

POSITION STATEMENT

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society

ABSTRACT

Objective: To update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2002 regarding the management of osteoporosis in postmenopausal women.

Design: NAMS followed the general principles established for evidence-based guidelines to create this updated document. A panel of clinicians and researchers expert in the field of metabolic bone diseases and/or women's health was enlisted to review the 2002 NAMS position statement, compile supporting statements, and reach consensus on recommendations. The panel's recommendations were reviewed and approved by the NAMS Board of Trustees.

Results: Osteoporosis, whose prevalence is especially high among elderly postmenopausal women, increases the risk of fractures. Hip and spine fractures are associated with particularly high morbidity and mortality in this population. Given the health implications of osteoporotic fractures, the primary goal of osteoporosis therapy is to prevent fractures, which is accomplished by slowing or stopping bone loss, maintaining bone strength, and minimizing or eliminating factors that may contribute to fractures. The evaluation of postmenopausal women for osteoporosis risk requires a medical history, physical examination, and diagnostic tests. Major risk factors for postmenopausal osteoporosis (as defined by bone mineral density) include advanced age, genetics, lifestyle factors (such as low calcium and vitamin D intake, smoking), thinness, and menopause status. The most common risk factors for osteoporotic fracture are advanced age, low bone mineral density, and previous fracture as an adult. Management focuses first on nonpharmacologic measures, such as a balanced diet, adequate calcium and vitamin D intake, adequate exercise, smoking cessation, avoidance of excessive alcohol intake, and fall prevention. If pharmacologic therapy is indicated, government-approved options are bisphosphonates, a selective estrogen-receptor modulator, parathyroid hormone, estrogens, and calcitonin.

Conclusions: Management strategies for postmenopausal women involve identifying those at risk of low bone density and fracture, followed by instituting measures that focus on reducing modifiable risk factors through lifestyle changes and, if indicated, pharmacologic therapy.

Key Words: Menopause – Osteoporosis – Fractures – Bone mineral density – Estrogen therapy – Hormone therapy – Bisphosphonate – Selective estrogen-receptor modulator – Calcitonin – Parathyroid hormone – Calcium – Vitamin D – NAMS.

Received February 27, 2006.

The Board of Trustees of The North American Menopause Society (NAMS) developed this manuscript with assistance from an Editorial Board composed of Bruce Ettinger, MD; Steven T. Harris, MD, FACP; David Kendler, MD; Bruce Kessel, MD; and Michael R. McClung, MD. It was edited, modified, and subsequently approved by the NAMS Board of Trustees on February 24, 2006.

The development of this position statement was supported by unrestricted educational grants from the Novartis Pharmaceuticals Corporation.

Address correspondence to: NAMS, P.O. Box 94527, Cleveland, OH 44101. E-mail: info@menopause.org.

Osteoporosis becomes a serious health threat for aging postmenopausal women by predisposing them to an increased risk of fracture. Osteoporotic fractures are associated with substantial morbidity and mortality in postmenopausal women, especially older women.

In response to the need to define standards of clinical practice in North America as they relate to menopause-associated health conditions, The North American Menopause Society (NAMS) has created this evidence-based position statement. The objective of this position statement is to provide guidance on the diagnosis, prevention, and treatment of osteoporosis in postmenopausal women to physicians, physician assistants, nurse practitioners, nurses, and other healthcare professionals caring for postmenopausal women, especially those in the clinical practice fields of obstetrics and gynecology, internal medicine, family medicine, and geriatrics.

This position statement is an update of the NAMS position statement published in 2002.¹ Since then, the publication of additional scientific evidence has created a need to update the position statement.

For this revision, NAMS conducted a search of the medical literature published since the previous position statement was submitted for publication in November 2001. A search was made for clinical trials, meta-analyses, and clinical practice guidelines published in English and related to osteoporosis in postmenopausal women using the database MEDLINE. The Medical Subject Headings (MeSH) used for the search were postmenopausal osteoporosis and bone loss with subheadings for epidemiology, etiology, diagnosis, prevention and control, and therapy. The National Guideline Clearinghouse was searched for relevant clinical practice guidelines and the Cochrane Library was searched for relevant systematic reviews. Priority was given to evidence from randomized controlled clinical trials and meta-analyses of such trials, followed by evidence from controlled observational studies, using criteria described elsewhere.²⁻⁴ Conclusions from other evidence-based guidelines also were reviewed. Because standards of care and available treatment options differ throughout the world, the focus is limited to therapies available in North America.

To help with this revision, NAMS enlisted a five-person Editorial Board composed of endocrinologists and gynecologists from both clinical practice and research with expertise in metabolic bone diseases and/or women's health. The Editorial Board reviewed the previous position statement and incorporated data

published since that statement, compiled supporting statements, and made recommendations. Where the evidence was contradictory or inadequate to form a conclusion, a consensus-based opinion was established. (Practice parameter standards related to NAMS position statements have been described in an editorial.⁵) The NAMS Board of Trustees was responsible for the final review and approval of this document. Updates to this revised position statement will be published as developments occur in scientific research that substantially alter the conclusions.

BACKGROUND

Osteoporosis—the most common bone disorder affecting humans—is a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture.⁶ Bone strength (and, hence, fracture risk) is dependent on both bone quality and bone mineral density (BMD).⁶ Expressed as grams of mineral per area or volume, BMD at any given age is a function of peak bone mass (reached around age 30 years) and how much bone is subsequently lost. Qualities of bone other than BMD (including degree of mineralization, hydroxyapatite crystal size, collagen structure, heterogeneity of bone microstructure, connectivity of trabeculae, and microdamage) are difficult or impossible to measure in clinical practice.

To standardize values from different bone densitometry tests, results are reported as either a Z-score or a T-score, with both expressed as standard deviation (SD) units.

- T-score is calculated by comparing current BMD to the mean peak BMD of a normal, young adult population of the same gender. For women, the reference database is white (non-race-adjusted) women aged 20 to 29 years. Use of T-scores is the preferred choice for postmenopausal women.
- Z-score is based on the difference between the woman's BMD and the mean BMD of a reference population of the same gender, age, and ethnicity.

NAMS supports the World Health Organization (WHO) definition⁷ of osteoporosis in a postmenopausal woman as a BMD T-score less than or equal to -2.5 at the total hip, femoral neck, or lumbar spine (posterior-anterior, not lateral) (see below). If anatomic factors such as obesity or arthritis make measurements invalid, the distal one-third radius bone density may be considered a diagnostic site. However, the relationship between the T-score at this site and fracture risk has not been systematically examined.

BMD-based definitions of bone density

Normal:	T-score above (ie, better than) -1.0
Low bone mass:*	T-score between -1.0 and -2.5
Osteoporosis:	T-score below (ie, worse than) or equal to -2.5

*osteopenia

From the World Health Organization.⁷

In addition to diagnosis through densitometry, osteoporosis can be diagnosed clinically, regardless of the T-score. Presence of a fragility fracture constitutes the clinical diagnosis of osteoporosis.

Peak bone mass is achieved during a woman's third decade of life.⁸ The process of bone loss begins at that time and accelerates at menopause. By age 80, many women have lost, on average, approximately 30% of their peak bone mass.⁹ However, osteoporosis is not always the result of bone loss. A woman who does not achieve an adequate peak bone mass as a young adult may have low bone mineralization without substantial bone loss as she ages.

Osteoporosis has no warning signs. Often, the first indication of the disease is a fracture. Nearly all nonvertebral fractures are caused by a fall; however, vertebral fractures often occur without a fall. Wrist fracture, which tends to occur at a younger age than vertebral or hip fracture, may also be an early clinical expression of osteoporosis.¹⁰

Osteoporosis is categorized as either primary or secondary. Primary osteoporosis is usually due to bone loss that occurs with aging. Secondary osteoporosis is a result of medications (eg, glucocorticoids), certain medical conditions (eg, hypogonadism), or diseases (eg, malabsorption) that adversely affect skeletal health.

The primary clinical goal of osteoporosis management is to reduce fracture risk. This may be accomplished by slowing or stopping bone loss, increasing bone mass or improving bone architecture, maintaining or increasing bone strength, and minimizing factors that contribute to falls. Management strategies include general preventive health measures and pharmacologic interventions.

Prevalence

Most cases of osteoporosis occur in postmenopausal women, and the prevalence of the disorder as defined by low BMD increases with age. Data from the Third National Health and Nutrition Examination Survey (NHANES III) indicate that 13% to 18% of white American women aged 50 or older have osteoporosis of the hip, which the survey defined as

femoral BMD greater than or equal to 2.5 SD below the mean of young, healthy white women (ie, T-score of -2.5).¹¹ Another 37% to 50% have osteopenia (or low bone mass) of the hip, defined as a T-score between 1 and 2.5 SD below the mean.¹¹ Prevalence increases from 4% in women 50 to 59 years old to 52% in women 80 and older.⁹

Osteoporosis as defined by low BMD is a common contributor to fractures, responsible for an estimated 90% of all hip and spine fractures in white American women aged 65 to 84 years.¹² However, most postmenopausal women with fractures do not have bone density values consistent with osteoporosis based on the WHO criterion.¹³ In the Study of Osteoporotic Fractures,¹⁴ the fracture risk attributable to osteoporosis (total hip BMD of -2.5 or less) was 28% for hip, 25% for spine, and 13% for all fractures. For BMD of -1.5 or less, the risks were 51%, 38%, and 25%, respectively. In a 2-year follow-up of women older than age 65, 49% of hip fractures occurred in women with total hip BMD T-scores better than -2.5 ; 28% occurred in women with T-scores better than -2.0 .¹⁵

For an American woman at age 50 years, the risk of suffering an osteoporotic fracture in her remaining lifetime has been estimated at 40%,¹⁶ with two thirds of the fractures occurring after age 75.¹⁷ The estimated remaining lifetime risks after age 50 years for hip, vertebral, and forearm fracture are 17.5%, 15.6%, and 16.0%, respectively.¹⁶

In the United States, the rates of osteoporosis and fracture vary with ethnicity. In one large study of postmenopausal women from five ethnic groups (white Americans, African Americans, Asian Americans, Hispanic Americans, and Native Americans),¹⁸ African Americans had the highest BMD, while Asian Americans had the lowest; only the BMD differences for African Americans were not explained by differences in weight. After adjusting for weight, BMD, and other covariates, white Americans and Hispanic Americans had the highest risk of osteoporotic fracture, followed by Native Americans, African Americans, and Asian Americans. The age-adjusted lifetime risks of hip fracture in US women are 17% for white Americans, 14% for Hispanic Americans, and 6% for African Americans.¹¹ These differences, however, may be related more to body size than to race.^{12,19}

Morbidity and mortality

Hip fractures, which occur on average at age 82 years, elicit a particularly devastating toll, resulting in higher cost, disability, and mortality than all other

osteoporotic fracture types combined. Hip fractures cause up to a 25% increase in mortality within 1 year of the incident. Approximately 25% of women require long-term care after a hip fracture, and 50% will have some long-term loss of mobility.²⁰

Fractures at other sites can also result in serious morbidity. Vertebral fractures occur, on average, in a woman's mid-70s. Multiple or severe vertebral fractures may cause substantial pain as well as loss of height and exaggerated thoracic kyphosis. Spinal pain and deformity can greatly restrict normal movement, including bending and reaching. Importantly, existing vertebral fractures greatly increase (fivefold to sevenfold) the risk of subsequent vertebral fracture.^{21,22} Thoracic fractures may restrict lung function and cause digestive problems.²³ In the Fracture Intervention Trial,²⁴ after an average of 3.8 years of follow-up, the relative risk of mortality was 6.7 (95% CI, 3.08-14.52) for hip fracture and 8.64 (95% CI, 4.45-16.74) for vertebral fracture.

Osteoporotic fractures take a psychological toll as well.²⁵ Hip and vertebral fractures and the resultant pain, loss of mobility, changed body image, and loss of independence can have a significant impact on self-esteem and mood.

PATHOPHYSIOLOGY

Bone remodeling is the process of bone resorption and bone formation. At the cellular level, osteoclasts promote bone resorption by stimulating the production of acid and enzymes that dissolve bone mineral and proteins. Osteoblasts promote bone formation by creating a protein matrix consisting primarily of collagen, which is soon calcified, resulting in mineralized bone.

In normal bone remodeling, bone resorption is balanced by bone formation. Bone loss occurs when there is an imbalance between bone resorption and bone formation, resulting in a decrease in bone mass and an increase in the risk of fracture.

Menopause is associated with a few years of rapid bone loss attributed to lower circulating levels of 17 β -estradiol, related primarily to the loss of estrogen-mediated inhibition of bone resorption without a fully compensatory increase in bone formation²⁶ However, there is only a weak association between serum estradiol levels and rates of bone turnover in postmenopausal women.

RISK FACTORS

In determining risk factors, it is important to distinguish between risk factors for *osteoporosis as defined*

TABLE 1. Risk factors for osteoporotic fracture

Advanced age
Low BMD
Previous fracture (other than skull, facial bone, ankle, finger, and toe) as an adult
History of hip fracture in a parent
Thinness [body weight <127 lb (57.7 kg) or low BMI (<21 kg/m ²)]
Current smoking, any amount
Low calcium or vitamin D intake
More than two alcoholic drinks per day
Oral or intramuscular glucocorticoid use for >3 mo
Increased fall risk
Impaired vision
Dementia
Poor health/frailty
Low physical activity
History of recent falls

BMD, bone mineral density; BMI, body mass index.

by BMD (both primary and secondary causes) and risk factors for *osteoporotic fracture*. For BMD-defined osteoporosis, major risk factors in postmenopausal women are advanced age, genetics, lifestyle factors (eg, low calcium and vitamin D intake, smoking), thinness, and menopause status. Risk factors for osteoporotic fracture are listed in Table 1; the most common are advanced age, low BMD, and previous fracture (other than skull, facial bone, ankle, finger, and toe) as an adult.

Risk factors for BMD-defined osteoporosis and osteoporotic fracture overlap, given that BMD is a risk factor for fracture. Importantly, however, many fracture risk factors are not related to BMD.

BMD and fracture risk

Bone density is an important determinant of fracture risk, especially in women aged 65 and older.^{27,28}

In general, lower BMD scores indicate more severe osteoporosis and higher risk of fracture. A decrease of 1 SD in BMD represents a 10% to 12% decrease in BMD and an increase in fracture risk by a factor of 1.5 to 2.6.^{29,30} BMD and fracture risk are most closely related when bone density is used to predict the fracture risk at that same site. Risks for spine fracture and hip fracture increase 2.3-fold and 2.6-fold, respectively, for each decrease of 1 SD in age-adjusted BMD at spine and hip, respectively.³⁰

Fracture risk, however, depends largely on factors other than BMD. Furthermore, a reliable marker to predict fracture risk or determine fracture risk reduction from therapy is not currently available. The use of BMD scores to assess fracture risk can be markedly improved by combining BMD with information about other risk determinants, particularly the

woman's age and fracture history. The WHO is currently developing a model to estimate the 10-year absolute fracture risk based on known risk factors. It will offer substantial benefits to healthcare providers compared with current methods.

Treatment-induced changes in BMD do not always correlate well with reductions in vertebral fracture risk.³¹⁻³⁴ In addition, fracture risk reductions in response to antiresorptive therapy occur much more rapidly than discernible BMD changes. For example, significant fracture risk reduction has been reported after 6 months of risedronate therapy,³⁵ although minimal BMD increases were observed at that time.³⁶

Advanced age

As women age, their risk of fracture increases. In general, the risk of osteoporotic fracture doubles every 7 or 8 years after age 50. The median age for hip fracture is 82 years. The median age for vertebral fracture is thought to occur in a woman's 70s.¹²

Older women are at substantially greater risk of fracture at any given BMD value.³¹ For example, at the same T-score of -2.5 , a 75-year-old woman has about 8 to 10 times the 10-year hip fracture risk of a 45-year-old woman.

Fracture history

In two analyses of studies, a peri- or postmenopausal woman who has had a fracture has approximately a 2.0 increased risk of sustaining another fracture; adjustment for BMD did not significantly affect the risk.^{22,37} A study of older women (mean age, 74 years) with recent vertebral fracture found that approximately 20% of these women experienced another vertebral fracture within 1 year of an incident vertebral fracture.²¹ However, the risk of recurrent fracture was significantly affected by the number of existing fractures—women with two or more vertebral fractures had a significantly increased risk (relative risk, 11.6) of another vertebral fracture within 1 year.

Genetics

The greatest influence on a woman's peak bone mass (ie, the maximal BMD gained during the skeletal development and maturation phase) is heredity. Studies have suggested that up to 80% of the variability in peak bone density might be attributable to genetic factors.^{38,39} Female children of women who have osteoporotic fractures have lower bone density than would be expected for their age.^{40,41} First-degree relatives (ie, mother, sister) of women with

osteoporosis also tend to have lower bone density than those with no family history of osteoporosis.⁴²

A history of fracture in a first-degree relative also significantly increases the fracture risk. In a meta-analysis,⁴³ a family history of fracture was found to be associated with significant increases in any osteoporotic fracture. Hip fracture risks were nearly 50% higher—127% higher if a hip fracture had occurred in a parent.

Lifestyle factors

Several lifestyle factors are associated with the risk of low BMD and fracture. These include nutrition, physical activity, cigarette smoking, and heavy alcohol consumption.

Nutrition

A balanced diet plays an important role in bone development and maintenance of bone health throughout life. Both calcium and vitamin D have well-known roles in bone metabolism. Adequate intake of calcium and vitamin D is required throughout life for a woman to achieve her genetically determined peak bone mass and to maintain optimal bone mass and strength after peak bone mass is attained.⁴⁴

Low vitamin D intake has been linked to impaired muscle strength, increased fall risk, and increased fracture risk along with increased rates of bone loss.⁴⁵ Furthermore, treatment with vitamin D has been found to reduce fracture risk in elderly postmenopausal women,⁴⁶⁻⁴⁹ although not in all studies.^{50,51} Elderly postmenopausal women have an increased risk of hip fracture associated with low dietary calcium intake.⁵²

Physical activity

There is general agreement that weight-bearing exercises confer a positive effect on the musculoskeletal system and that weight-bearing exercises (eg, walking, running, step aerobics, gymnastics) provide the greatest osteogenic stimulus.⁵³⁻⁵⁵ The effects of exercise on bone mass could be caused by osteoblast activity.⁵⁶

Regular exercise has been associated with reduced fracture risk.⁶ Exercise also appears to reduce the risk of falls by increasing muscle mass, strength, and balance, although it is unclear whether exercise affects the risk of fracture from falls that do occur.⁶

Long-term immobilization, such as prolonged bed rest, has been associated with rapid and significant bone loss.^{57,58} However, no evidence indicates that a sedentary lifestyle increases the risk of bone loss.

Cigarette smoking

Compared with nonsmokers, women smokers tend to lose bone more rapidly, have lower bone mass, and reach menopause 2 years earlier, on average.⁵⁹⁻⁶¹ In addition, some data show that postmenopausal women who currently smoke have significantly higher fracture rates than nonsmokers.⁶² The risk imparted by smoking remains significant even after adjusting for BMD.⁶³

The mechanisms by which smoking might adversely affect bone mass are not known, although evidence suggests that cigarette smokers may have impaired calcium absorption^{59,64,65} and lower 17 β -estradiol levels.⁶⁶

Alcohol consumption

Heavy alcohol consumption [defined in the Framingham Study as ≥ 7 oz/wk (200 mL/wk)]⁶⁷ has been shown to increase the risk of falls and hip fracture. A recent meta-analysis⁶⁸ showed that consuming as few as two drinks per day significantly increases the fracture risk. Very heavy alcohol consumption also has detrimental effects on BMD. However, moderate alcohol consumption [1-2 oz/wk (30-60 mL/wk)] in women 65 years of age and older is associated with higher BMD⁶⁹ and decreased risk of hip fracture.⁷⁰

Thinness

Being thin—often cited as body weight less than 127 lb (57.7 kg), the lower quartile of weight for US women older than age 65, or a body mass index (BMI) less than 21 kg/m²—is a risk factor for low BMD.⁷¹ Thinness has also been associated with increased fracture risk, especially in older women.⁷² In a meta-analysis of population-based cohort studies,⁷³ a BMI of 20 kg/m² conferred nearly a twofold increased risk of fracture compared with a BMI at the upper range of normal (≥ 25 kg/m²). Being thin seems to have its primary effect on fracture risk by its association with low bone density.

Menopause status

The increased rate of bone resorption immediately after menopause clearly indicates a hormonal influence on bone density in women. The most likely explanation for this increased resorption is the drop in ovarian estrogen production that accompanies menopause.

Bone loss begins to accelerate approximately 2 to 3 years before the last menses, and this acceleration

ends 3 to 4 years after menopause. For an interval of a few years around menopause, women lose 2% of bone annually. Afterward, bone loss slows to about 1% to 1.5% per year.^{74,75} A prospective, longitudinal study of white women reported BMD losses during this 5- to 7-year interval of 10.5% for the spine, 5.3% for the femoral neck, and 7.7% for the total body.⁷⁴ Although some of the decline can be attributed to age-related factors, lower estrogen levels were implicated as the cause for approximately two thirds of the bone loss. Lower estrogen levels have also been significantly associated with increased fracture risk in older women (mean age, 75 years).⁷⁶

Women experiencing menopause at or before age 40—either spontaneously or induced (eg, through bilateral oophorectomy, chemotherapy, pelvic radiation therapy)—are at greater risk of low BMD than other women of the same age who have not reached menopause.⁷⁷ However, by age 70, when fractures are more likely to occur, these women have the same risk of low BMD or fracture as women who reached menopause at the average age.^{78,79}

Secondary causes of bone loss

Various medications, disease states, and genetic disorders are associated with bone loss (Table 2). Oral glucocorticoid use causes the most common form of drug-related osteoporosis. Evidence suggests that high-dose inhaled glucocorticoids may cause bone loss.^{80,81} Other studies^{82,83} suggest that no effect occurs with the approved doses of inhaled steroids. In a meta-analysis of seven population-based cohort studies (N = 42,500 men and women),⁸⁴ current and previous oral glucocorticoid use was found to be significantly associated with increased risk of osteoporotic fracture. This risk appears within 3 months of beginning corticosteroid use.

Current use of two drugs prescribed for premenopausal women—gonadotropin-releasing hormone (GnRH) and intramuscular medroxyprogesterone acetate (MPA)—has been associated with bone loss. Use of GnRH contributes to bone loss by creating iatrogenic hypogonadism.⁸⁵ Bone loss with short-term use of GnRH agonist therapy is reversible. Bone loss with long-term use can be ameliorated by “adding back” low-dose estrogen therapy. Use of depot MPA (150 mg/3 months) as a contraceptive has been associated with bone loss.^{86,87} This bone loss, which has never been linked to the occurrence of osteoporotic fracture, has been shown to be reversible in some studies; however, other studies have indicated that BMD only partially recovers.⁸⁸

TABLE 2. *Secondary causes of bone loss*

Medications
Oral or intramuscular use of glucocorticoids for >3 mo
Excessive thyroxine doses
Aromatase inhibitors
Long-term use of certain anticonvulsants (eg, phenytoin)
Heparin
Cytotoxic agents
Gonadotropin-releasing hormone agonists or analogues
Intramuscular medroxyprogesterone contraceptive
Immunosuppressives (eg, cyclosporine)
Genetic disorders
Osteogenesis imperfecta
Thalassemia
Hypophosphatasia
Hemochromatosis
Disorders of calcium balance
Hypercalciuria
Vitamin D deficiency
Endocrinopathies
Cortisol excess
Cushing's syndrome
Gonadal insufficiency (primary and secondary)
Hyperthyroidism
Type 1 diabetes mellitus
Primary hyperparathyroidism
Gastrointestinal diseases
Chronic liver disease (eg, primary biliary cirrhosis)
Malabsorption syndromes (eg, celiac disease, Crohn's disease)
Total gastrectomy
Billroth I gastroenterostomy
Other disorders and conditions
Multiple myeloma
Lymphoma and leukemia
Systemic mastocytosis
Nutritional disorders (eg, anorexia nervosa)
Rheumatoid arthritis
Chronic renal disease

Medical conditions associated with bone loss include excess urinary calcium excretion, which may be caused by a renal calcium leak or hyperthyroidism. Vitamin D deficiency, an especially common condition in the older women, is a correctable cause of secondary hyperparathyroidism and accelerated bone loss. Other conditions that can have a detrimental effect on bone include multiple myeloma, endocrine disorders such as hyperparathyroidism and Cushing's syndrome, and disorders of collagen structures. Renal failure can cause either increased bone resorption (secondary/tertiary hyperparathyroidism) or decreased bone formation, leading to renal osteodystrophy.

EVALUATION

All postmenopausal women should be assessed for risk factors associated with osteoporosis and fracture. This assessment requires a history, physical examination, and any necessary diagnostic tests. The

goals of this evaluation are to identify risk factors for fractures, including whether osteoporosis is present, and, if so, assessing its severity, ruling out secondary causes for osteoporosis, and identifying modifiable risk factors for falls and injuries.

History and physical examination

The medical history and physical examination should focus on the detection of clinical risk factors for osteoporosis and fracture. This includes a personal history of fracture as well as a history of hip fracture in a parent. Most of these risks can be uncovered with a simple questionnaire. Although risk factors may help identify contributing causes of osteoporosis or help guide therapeutic recommendations, they cannot be used to diagnose osteoporosis.

Loss of height may be a sign of vertebral fracture. After achieving maximal height, women (and men) can lose up to 1.0 to 1.5 inches (2-3 cm) of height as part of the normal aging process, primarily as a result of shrinkage of intervertebral disks. Height loss greater than 1.5 inches (3 cm) increases the likelihood that a vertebral fracture is present.⁸⁹ Height should be measured annually with an accurate method, such as a wall-mounted ruler or a stadiometer. Loss of 1.5 inches (3 cm) or more calls for evaluation by a lateral thoracolumbar radiograph to identify silent vertebral fractures.

Weight also should be recorded to identify those with a body weight of 127 lb (57.7 kg) or lower and to calculate BMI.

The examination should include an assessment for acute or chronic back pain, especially in the middle back, which may indicate the presence of vertebral fractures. The midback vertebrae T11-12 and L1 are the most common fracture sites, followed by T6 through T9.⁹⁰⁻⁹² Multiple, severe vertebral compression fractures ultimately result in kyphosis (abnormal curvature of the thoracic spine), the most obvious sign of osteoporosis.

Because back pain, height loss, and kyphosis can occur without osteoporosis, and two thirds of vertebral fractures are asymptomatic,^{93,94} vertebral fracture must be confirmed, usually by lateral spine radiographs. In addition, some dual energy x-ray absorptiometry (DXA) techniques (eg, instant vertebral assessment, morphometric x-ray absorptiometry) allow vertebral fracture assessment and, hence, can be used to visualize a fracture at the same time that BMD is being measured.^{95,96} Height loss of more than 20% (or 4 mm) of the anterior, mid, or posterior

dimension of a vertebra on spinal radiograph is also indicative of vertebral fracture.^{97,98}

After menopause, a woman's risk of falls should be assessed at least annually. Clinical factors related to an increased risk of falls include the following:

- A history of falls, fainting, or loss of consciousness
- Muscle weakness or coordination
- Dizziness or balance problems
- Difficulty standing or walking
- Arthritis
- Impaired vision

The risk of falls is also increased by use of medications that affect balance and coordination (eg, sedatives, narcotic analgesics, anticholinergics, anti-hypertensives) or by use of multiple medications.⁹⁹

The greater the number of risk factors, the greater the risk is of falling. In one study, having four or more of these risk factors increased the risk of falls by nearly 80%.¹⁰⁰

Safety hazards in the home and work environment, such as obstacles and poor lighting, also contribute to the risk of falls. These hazards can be assessed by questioning the woman or through a home and/or workplace visit by an occupational therapist or other healthcare professional knowledgeable in fall prevention.

Bone mineral density measurement

BMD testing is the technical standard for diagnosing osteoporosis. Determinants of bone strength other than bone density cannot be measured in the clinical setting.

Indications for BMD testing

Testing of BMD should be performed based on a woman's risk profile. Testing is not indicated unless the results will influence a treatment or management decision. Other factors such as availability of BMD testing equipment and reimbursement by insurance also affect the decision to measure BMD.

NAMS recommends that BMD be measured in the following populations:

- Postmenopausal women with medical causes of bone loss, regardless of age
- Postmenopausal women at least 65 years of age, regardless of additional risk factors

Testing should be considered for healthy postmenopausal women younger than age 65 when one or more of the following risk factors for fracture have

been identified (the greater the number of risk factors, the greater is the need for testing):

- Fracture (other than skull, facial bone, ankle, finger, and toe) after menopause
- Thinness [body weight <127 lb (57.7 kg) or BMI <21 kg/m²]
- History of hip fracture in a parent
- Current smoker

BMD testing options

Several tests to measure BMD are available. DXA is the preferred technique for measuring central (eg, spine, hip) BMD and for diagnosing osteoporosis because it measures BMD at the important sites of osteoporotic fractures.¹⁰¹

When BMD testing is indicated, NAMS recommends measuring the total hip, femoral neck, and posterior-anterior lumbar spine, and using the lowest of the three BMD scores. In some older patients (older than 60 years), there can be artifacts of the spine that make measurements unreliable. The spine, however, is a useful site for BMD measurement in early postmenopausal women because they tend to lose bone faster in the spine than in the hip.

Although tests at peripheral sites (eg, wrist, calcaneus) can identify women with low bone mass, they are not as useful as central-site tests because the prediction of risk with the results is not well determined. WHO diagnostic criteria cannot be applied to peripheral sites with the exception of the distal radius, although BMD measurement has been predictive of fracture risk.¹⁰² Peripheral site measurements should be limited to the assessment of fracture risk when DXA is not available. They cannot be used to diagnose osteoporosis or to follow response to therapy.¹⁰³

Follow-up BMD testing

In most cases, repeat DXA testing in untreated postmenopausal women is not useful until 3 to 5 years have passed, given the rate of bone loss of 1% to 1.5% per year. Postmenopausal women, after substantial BMD losses in early postmenopause, generally lose about 0.5 T-score units every 5 years.^{74,104}

For women receiving osteoporosis therapy, BMD monitoring may not provide clinically useful information until after 2 years of treatment. The lack of an increase in BMD is not evidence of treatment failure. In two randomized controlled trials, most women who appeared to have lost more than 4% of BMD during the first year of treatment with either alendronate or

raloxifene showed substantial gains the second and third years while remaining on the same therapy.^{105,106} This variability was seen despite excellent quality assurance programs and is a consequence of the imprecision of DXA testing.

A statistically *insignificant* decrease in BMD on treatment may be related to imprecision in the DXA measurement rather than to treatment failure. However, a statistically *significant* decrease in BMD (usually >4%-5%) would warrant further consideration of secondary causes of bone loss and evaluation of adherence to therapy.

Bone turnover markers

Biochemical markers of bone turnover cannot diagnose osteoporosis and have varying ability to predict fracture risk. Nevertheless, these tests have been studied as a means to assess therapeutic response earlier than through BMD changes, sometimes within a few months as opposed to the 1 to 3 years required with BMD.¹⁰⁷⁻¹⁰⁹ However, bone turnover markers vary from day to day, are affected by food intake and time of day, and lack assay standardization, limiting their clinical utility.

The value of bone turnover markers in routine clinical practice has not been established. Although some clinicians have found that these data can encourage adherence to therapy, several trials have found no difference in adherence when marker values are communicated to women.^{110,111}

Tests for secondary causes

Once osteoporosis is diagnosed, any secondary causes should be identified. Various laboratory tests can be useful (Table 3). Routine tests include a complete blood cell count plus serum levels of calcium, 25-hydroxyvitamin D, alkaline phosphatase, and albumin, as well as urinary calcium excretion to identify calcium malabsorption or renal calcium leak. If the clinical history, physical examination, or routine laboratory tests indicate a need, special tests that may be appropriate include measurement of thyroid-stimulating hormone, urinary cortisol, serum protein electrophoresis, and parathyroid hormone.

MANAGEMENT: LIFESTYLE APPROACHES

All postmenopausal women, regardless of their osteoporosis risk factors, should be encouraged to take steps to prevent bone loss and fractures, such as eating a balanced diet, obtaining adequate calcium

and vitamin D, participating in appropriate exercise, not smoking, avoiding excessive alcohol consumption, and instituting measures to prevent falls. These steps offer health benefits beyond their effects on osteoporosis.

Nutrition

A balanced diet is important for bone development as well as for general health. Some populations, such as elderly women (older than age 65) with reduced appetites or women who diet frequently or have eating disorders, may not consume adequate vitamins and minerals to maintain optimal bone mass. Elderly women who lose weight, purposely or not, run the risk of accelerated bone loss and a higher risk of hip fracture.¹¹² In general, women should be advised to maximize consumption of fruits and vegetables and minimize consumption of fats.

For women older than age 75, data from the Framingham Osteoporosis Study, a longitudinal cohort study, suggest that adequate protein intake may help minimize bone loss.^{113,114} Protein supplements (20 g/day) in older patients (mean age, 82 years) who have sustained a hip fracture have been shown to significantly shorten the hospital stay (median stay, 69 days vs 102 days for placebo recipients) after

TABLE 3. Routine laboratory tests for osteoporosis evaluation

Test	Diagnostic result	Possible secondary cause
Complete blood cell count	Anemia	Multiple myeloma
Serum calcium	Elevated Low	Hyperparathyroidism Vitamin D deficiency, GI malabsorption
Serum 25-hydroxyvitamin D	Low	GI malabsorption, celiac disease
Serum albumin	Used to interpret serum calcium	
Serum alkaline phosphatase	Elevated	Vitamin D deficiency, GI malabsorption, hyperparathyroidism, Paget's disease
Urinary calcium excretion	Elevated	Renal calcium leak, multiple myeloma, metastatic cancer involving bone, hyperparathyroidism, hyperthyroidism
	Low	GI malabsorption, inadequate intake of calcium and vitamin D

GI, gastrointestinal.

hip fracture and improve the clinical outcomes while in the hospital.¹¹⁵ Compared with the controls, protein recipients also had significantly lower rates of complications and mortality 7 months after their hip fracture.

An adequate intake of both calcium and vitamin D is important for bone health, and it is recognized as an important component of any osteoporosis prescription-drug regimen. For example, a review of 31 clinical trials evaluating estrogen therapy with and without calcium supplements found annual BMD gains at the hip were significantly greater for those receiving estrogen plus calcium (2.4%) compared with estrogen alone (0.9%).¹¹⁶

Calcium, either alone or with vitamin D, is not as effective as pharmacotherapy with either estrogen alone (ET) or estrogen plus progestogen (EPT), a selective estrogen-receptor modulator (SERM), or a bisphosphonate. Nevertheless, calcium and vitamin D are both important components of osteoporosis therapy in combination with all antiresorptive agents.

Calcium

Evidence has established the role of adequate calcium intake on bone health, primarily in increasing BMD and improving the efficacy of therapeutic agents. Calcium has not been shown to have a positive effect on fracture risk;^{50,117} however, in the Women’s Health Initiative (WHI) trial,¹¹⁷ hip fractures were significantly reduced in older women who were adherent to the calcium regimen.

Calcium requirements increase with advancing age, particularly after menopause, owing in part to both reduced intestinal calcium absorption and renal calcium conservation. The primary factor influencing the amount of calcium absorbed is the amount of calcium ingested.

Most experts support the published recommendations for daily calcium consumption from either the

National Institutes of Health (revised in 1994)¹¹⁸ or the National Academy of Sciences (revised in 1997).¹¹⁹ Recommendations related to peri- and postmenopausal women are presented in Table 4.

No single laboratory test can accurately detect calcium deficiency. However, a 24-hour urine calcium level of less than 50 mg suggests either insufficient intake or poor absorption. In general, postmenopausal women in the United States and Canada have dietary calcium intakes that are low, with median intakes of approximately 600 mg/day.^{120,121} Specific populations of postmenopausal women at increased risk of inadequate calcium intake include women who are older, are lactose intolerant, follow a vegetarian diet, or have poor eating habits.

Dietary sources should be the primary source of calcium intake because of the other essential nutrients found in high-calcium food. Dairy products are the best sources of calcium based on their high elemental calcium content, high absorption rate, and low cost relative to total nutritional value. To achieve maximal calcium absorption from food sources, food selection decisions should reflect the food’s calcium bioavailability and the presence in the meal of other foods that may inhibit calcium absorption (eg, oxalic acid-containing foods, such as spinach, and phytate-rich grains, such as wheat bran).¹²²

Calcium supplements and calcium-fortified foods are alternative sources for women unable to consume enough dietary calcium; most women need an additional 600 to 900 mg/day (two to three dairy portions) over their usual daily intake to reach recommended levels. Calcium citrate supplements are well absorbed when taken with meals or on an empty stomach; calcium carbonate is better absorbed when taken with food. It is best to take calcium in divided doses for better absorption, although single doses of up to 1,000 mg can be taken.

Total calcium intakes of up to 1,500 mg/day do not appear to increase the risk of developing renal calculi and may actually reduce it.¹²³ Calcium supplements are contraindicated in a woman with a calcium-containing renal calculus until her urinary biochemical profile has been assessed. Larger amounts of calcium (>2,500 mg/day) should be avoided.

Calcium intervention trials have not reported any serious adverse events. Nevertheless, some women have difficulty swallowing the large tablet or have gastrointestinal (GI) adverse effects (ie, gaseousness, constipation). Tolerability can be addressed by switching the type of calcium or reducing the dose. GI adverse effects are often related to a woman’s

TABLE 4. Recommended daily elemental calcium intake in peri- and postmenopausal women

National Academy of Sciences	
Age 31-50	1,000 mg
Age 51 and older	1,200 mg
National Institutes of Health	
Premenopausal women aged 25-50	1,000 mg
Postmenopausal women younger than age 65 and using estrogen therapy	1,000 mg
Postmenopausal women not using estrogen therapy	1,500 mg
All women aged 65 and older	1,500 mg

Adapted from the National Institutes of Health¹¹⁸ and the National Academy of Sciences.¹¹⁹

taking more calcium than required, not dividing doses, or perhaps confusing supplemental intake with recommended total daily intake.

Vitamin D

The nutrient vitamin D is essential for the intestinal absorption of calcium. The current National Academy of Sciences recommended dietary intake for vitamin D is 400 IU/day for women aged 51 to 70 years and 600 IU/day for women older than age 70.¹¹⁹ In addition, NAMS recommends intake of 700 to 800 IU/day for women at risk of deficiency because of inadequate sunlight exposure, such as older, frail, chronically ill, housebound, or institutionalized women or those who live in northern latitudes.¹²⁴ Doses as high as 2,000 IU/day are safe.¹¹⁹ Much higher doses may introduce risks such as hypercalciuria and hypercalcemia.

Sources of vitamin D include sunlight, vitamin D–fortified dairy products, fatty fish, and supplements. Daily requirements can usually be met with a multivitamin supplement (typically containing 400 IU vitamin D), vitamin D–fortified foods (eg, milk, breakfast cereals providing 100 IU per serving), or calcium supplements containing vitamin D (usually 200 IU per tablet). Many women over the age of 65 who have little or no sun exposure and rely on multivitamins alone for vitamin D intake may have suboptimal vitamin D levels.¹²⁵ Currently, there is no worldwide consensus on criteria for acceptable serum 25-hydroxyvitamin D values, but if parathyroid hormone concentration were used as an index of calcium absorption, as some suggest, the lower end of the normal 25-hydroxyvitamin D concentration would be in the range of 30 ng/mL (70–80 nmol/L).¹²⁶ Because of the long half-life of vitamin D, taking vitamin D at the same time as calcium is not necessary, although it can be a convenient way to obtain adequate intake of both nutrients.

Regarding the effect of vitamin D on fracture risk, several large randomized controlled studies of vitamin D (400 and 800 IU/day) plus 1,000 mg calcium^{50,51,117} have shown that the nutrients do not have a significant effect on fracture risk. However, a meta-analysis⁴⁹ of randomized clinical trials in postmenopausal women (mean ages, 71–85 years) found that a vitamin D dose of 700 to 800 IU/day was associated with significant reductions in the risk of both hip and nonvertebral fractures. No significant changes were found in either fracture outcome in trials that used only 400 IU/day.

Studies have found that vitamin D (600–700 IU/day) with supplemental calcium can reduce the rate of postmenopausal bone loss, especially in older women.¹²⁷ More recent results from the WHI¹¹⁷ found calcium (1,000 mg/day) plus vitamin D (400 IU/day) recipients had a small but significant 1% improvement in hip BMD. Vitamin D supplementation also has been found to improve muscle strength¹²⁸ and balance,¹²⁹ and reduce the risk of falling.¹³⁰

Vitamin K

Supplementation with vitamin K (1 mg/day) appears to be associated with beneficial effects on bone turnover and bone density. Taking vitamin K as part of a daily multivitamin supplement may contribute to reducing postmenopausal bone loss, especially in the hip,¹³¹ but further validation is needed to define its contribution. Vitamin K supplements are contraindicated in women taking warfarin.

Magnesium

Another nutrient, magnesium, is sometimes mentioned as a necessary supplement for the protection of bone health and/or for absorption of calcium. However, in most trials focused on BMD or osteoporotic fracture, benefits of calcium were observed without magnesium supplements. Moreover, a study with calcium absorption as the end point found that adding 789 to 826 mg/day of magnesium, more than double the daily average magnesium intake (280 mg) for postmenopausal women, had no effect on calcium absorption.¹³² Nevertheless, in women with excessive magnesium loss, usually due to GI disease (eg, diarrhea, vomiting), magnesium supplementation would be appropriate.^{133,134}

Isoflavones

Clinical trial data do not support the use of isoflavones (a class of phytoestrogens found in rich supply in soybeans and soy products as well as in red clover) to prevent or treat osteoporosis. Although some data suggest that isoflavones may favorably affect bone health,¹³⁵ accumulating data from several more recent studies indicate a lack of bone benefits from isoflavones, regardless of the source (ie, extracted from red clover or soy or consumed in soy foods).^{136–138} Ipriflavone, a synthetic isoflavone available without a prescription in the United States and Canada, has not demonstrated a positive effect on bone density, bone turnover markers, or fracture risk in women with osteoporosis.¹³⁹

Exercise

Local increases in bone mass occur in response to activities that cause significant stress to bone. Active exercises that involve weight training can increase bone mass if they increase muscle mass and strength. Applying passive stress tests to bone also shows promise, with the most positive results coming from use of high-frequency, whole-body vibration systems.^{140,141}

In early postmenopausal women, strength training provides small but significant benefits on bone mass.¹⁴² A meta-analysis¹⁴³ found that women who exercised increased spinal BMD by approximately 2%. For women who use menopausal estrogen-containing therapy, strength training provides additional BMD benefits over hormone therapy alone.¹⁴⁴ Most strength training studies have used progressive resistance obtained with machines designed for this purpose (eg, Nautilus). However, strength training can be performed as few times as twice a week and need not involve expensive equipment. Exercise for women with established osteoporosis should not include heavy weight-bearing exercises or activity so vigorous that it may trigger a fracture.

For elderly women with osteoporosis, physical activity plays an important role in reducing the risk of falls. Among women aged 75 and older, muscle-strengthening and balance exercises have been shown to reduce the risk of falls and fall-related injuries by 75%.¹⁴⁵

Fall prevention

Falls are the precipitating factor in nearly 90% of all fractures.¹⁴⁶ In the United States and Canada, approximately one third of women older than age 60 fall at least once a year.^{100,147} In nearly one half of these cases, it is a recurrent fall. The incidence of falls increases with age, rising to a 50% annual rate in people older than age 80. Elderly women have a significantly higher risk of falls than do men of the same age. As a result, prevention of falls that can cause fractures should be an aspect of routine care for all postmenopausal women.

Several healthcare interventions have proven effective in reducing the risk of falls. These focus primarily on exercises to improve balance and muscle strength, adjusting medication use (especially psychotropic drugs), and reducing fall hazards in the home.¹⁴⁸ Tapering or discontinuing use of benzodiazepines, neuroleptic agents, and antidepressants has been found to reduce the risk of falling by more

TABLE 5. Recommendations for fall prevention

Lighting	Provide ample lighting
	Have easy-to-locate light switches for rooms and stairs
	Use night lights to illuminate walkways
Obstructions	Remove clutter, low-lying objects
	Remove raised door sills to ensure smooth transition
Floors and carpets	Provide nonskid rugs on slippery floors
	Repair/replace worn, buckled, or curled carpet
	Use nonskid floor wax
Furniture	Arrange furniture to ensure clear pathways
	Remove or avoid low chairs and armless chairs
	Adjust bed height if too high or low
Storage	Install shelves and cupboards at accessible height
	Keep frequently used items at waist height
Bathroom	Install grab bars in tub, shower, near toilet
	Use chair in shower and tub
	Install nonskid strips/decals in tub/shower
	Elevate low toilet seat or install safety frame
Stairways and halls	Install handrails on both sides of stairs
	Remove or tape down throw rugs and runners
	Repair loose and broken steps
	Install nonskid treads on steps

than 60%.¹⁴⁹ Implementing relatively inexpensive measures to eliminate safety hazards in the home may also reduce this risk (Table 5), but home hazard intervention studies have failed to show significant reductions in fracture.¹⁴⁸

Hip protectors worn during the day have been shown to reduce the likelihood of hip and pelvis fractures from falls among elderly postmenopausal women (aged 75 years and older) with a history of frequent falls.¹⁵⁰ However, a Cochrane review¹⁵¹ found the overall evidence inconclusive regarding efficacy in reducing hip fractures. Furthermore, the adherence rates in studies were low, averaging approximately 50%, primarily due to the inconvenience of wearing the protective garment day and night.

Smoking cessation

Because smoking can lead not only to lower BMD but also to a wide range of health problems, including increased fracture risk, smoking cessation should be encouraged for all smokers. A wide array of smoking cessation aids are available, including prescription products (with and without nicotine) and behavior-modification programs.

Alcohol avoidance

The level of alcohol consumption associated with an increased risk of falls is more than seven drinks a

week, as established by the Framingham Heart Study.⁷⁰ Postmenopausal women who drink should be advised to drink moderately and not to exceed seven drinks a week. One drink is considered to be one 12-oz (360 mL) beer, 4 oz (120 mL) of wine, or 1 oz (30 mL) of liquor.

MANAGEMENT: PHARMACOLOGIC APPROACHES

A management strategy focused on lifestyle approaches may be all that is needed for postmenopausal women who are at low risk of osteoporotic fracture. NAMS recommends adding osteoporosis drug therapy in the following populations:

- All postmenopausal women who have had an osteoporotic vertebral fracture
- All postmenopausal women who have BMD values consistent with osteoporosis (ie, T-scores equal to or worse than -2.5)
- All postmenopausal women who have T-scores from -2.0 to -2.5 and at least one of the following risk factors for fracture: thinness [body weight <127 lb (57.7 kg) or low BMI (<21 kg/m²)], history of fragility fracture since menopause, or history of hip fracture in a parent

The diagnostic categorization should be based on the lowest of the BMD values among the three measured sites of total hip, femoral neck, and posterior-anterior lumbar spine. Current treatment guidelines are based on specific bone density thresholds and risk factors. Available in the near future will be an improved method from the WHO that uses algorithms that incorporate estimates of absolute fracture risk.

Several pharmacologic options are available for osteoporosis therapy, including bisphosphonates, the SERM raloxifene, parathyroid hormone, estrogens, and calcitonin. No studies have compared these therapies for antifracture efficacy.

Adherence to therapy is poor. In studies of 6 months to 1 year, adherence rates for prescription drugs ranged from below 25% to 81%, depending on the therapy.¹⁵²⁻¹⁵⁴ Ensuring adherence to the treatment plan is perhaps the most important follow-up measure for clinicians.

Bisphosphonates

This class of drugs works by inhibiting the activity of osteoclasts and shortening their life span, thereby

reducing bone resorption.¹⁵⁵ Bisphosphonates do not have known beneficial effects on the body other than on bone. The most common adverse effect of bisphosphonate therapy is esophageal and gastric irritation, particularly affecting individuals who dose inappropriately. Before starting bisphosphonate therapy, serum creatinine should be used to estimate the glomerular filtration rate; treatment may be initiated only if the rate is 30 mL/min or greater.

Clinical trials have demonstrated that bisphosphonates significantly increase BMD at the spine and hip in a dose-dependent manner in both younger and older postmenopausal women. In women with osteoporosis, bisphosphonates have reduced the risk of vertebral fractures by 40% to 50% and reduced the incidence of nonvertebral fracture, including hip fracture, by about half this amount.^{106,155}

All the bisphosphonates approved for osteoporosis therapy in both the United States (alendronate, ibandronate, and risedronate) and Canada (alendronate, etidronate, and risedronate) are available in oral formulations for daily and intermittent dosing regimens. Weekly oral dosing regimens of alendronate and risedronate and monthly oral dosing regimens and IV dosing of ibandronate have been approved based on clinical trials that showed BMD responses equivalent to those observed with daily treatment.¹⁵⁶⁻¹⁵⁹ All fracture data are from trials with daily dosing; the bridging studies beyond daily dosing were not designed with fracture end points.

Alendronate

This bisphosphonate, marketed as Fosamax, is approved in both the United States (as an oral tablet and liquid) and Canada (oral tablet only) for postmenopausal osteoporosis prevention (5 mg/day or 35 mg/wk) and treatment (10 mg/day or 70 mg/wk). Alendronate is also available in a single weekly oral tablet of 70 mg with 2,800 IU of vitamin D (Fosamax Plus D).

For women in early postmenopause, 2 to 6 years of treatment with alendronate (5 mg or more daily) has been shown to significantly increase BMD at the spine and hip by approximately 1% to 4% from baseline, whereas BMD in placebo recipients decreased by 2% to 4% during that time.^{160,161} In older women with osteoporosis,¹⁶² therapy with 10 mg daily significantly increased BMD in the spine (8.8%) and the femoral neck (5.9%) after 3 years, compared with placebo. In 7- and 10-year trials in women with low bone density,^{163,164} alendronate therapy resulted in increases from baseline of 5% to

10% at the spine and hip in postmenopausal women who had low BMD or established osteoporosis. Because placebo groups were not followed for the duration of the studies,^{163,164} the antifracture effects of long-term alendronate therapy could not be adequately evaluated. However, there was no apparent increase in fracture risk over time.

The efficacy of alendronate in decreasing fracture risk has been demonstrated only in postmenopausal women with osteoporosis. Similar to other bisphosphonates, alendronate has shown lesser effects in women without osteoporosis.

In the Fracture Intervention Trial (FIT),¹⁶⁵ daily alendronate therapy for 2.9 years significantly reduced the risk of vertebral fracture by 47% and of hip fracture by 51% in women with low BMD and previous vertebral fracture. The incidence of clinical vertebral fractures was reduced by 59% within the first year.¹⁶⁶ In a composite analysis of the two arms of the FIT study,¹⁶⁶ 3 years of alendronate therapy in a subgroup of women with osteoporosis (ie, vertebral fracture or T-score equal to or worse than -2.5) significantly reduced the risk of nonspine fracture by 27% and new spine fracture by 50%.

Risedronate

This bisphosphonate, marketed as Actonel, is approved for the prevention and treatment of postmenopausal osteoporosis in oral tablet doses of 5 mg daily or 35 mg once weekly. Recently available in the United States is a packet containing both risedronate and calcium (marketed as Actonel with Calcium) that provides 4 weeks of risedronate therapy (35 mg/wk) and calcium carbonate (500 mg for the no-risedronate days).

In a randomized clinical trial of early postmenopausal women (age range, 40-61 years; mean age, 51-52 years) with normal bone density, risedronate doses of 5 mg/day for 2 years produced significant BMD increases of 5.7% in the lumbar spine and 5.4% in the hip greater than with placebo.¹⁶⁷ In a randomized controlled trial in older postmenopausal women (mean age, 68-69 years),³⁶ 3 years of risedronate therapy (5 mg/day) resulted in significant BMD increases of 4.3% in the spine and 2.8% in the femoral neck compared with placebo. Therapy for 7 years resulted in progressive increases in BMD of 11.5% from baseline (with no placebo group after 5 years).¹⁶⁸

Several randomized controlled trials have found fracture risk reductions with risedronate. In two trials of postmenopausal women with osteoporosis,^{36,169}

1 to 3 years of treatment with 5 mg/day of risedronate significantly reduced the risk of vertebral fracture (41%-49%) compared with placebo. Within the first year of therapy, the relative risk of vertebral fracture was reduced by 61% to 65%. After 3 years of therapy, vertebral fracture risk reductions were still statistically significant relative to placebo. In one of these trials,³⁶ the risk of nonvertebral fracture was significantly reduced by 39%. In the other trial,¹⁶⁹ nonvertebral fracture risk was reduced by 33%, although this was not statistically significant versus placebo.

In the Hip Intervention Program Study Group,¹⁷⁰ a randomized controlled trial of 5,445 postmenopausal women aged 70 to 79 years, daily risedronate therapy significantly reduced the relative risk of hip fracture by 40% in women with BMD values consistent with osteoporosis. It reduced the risk of hip fracture by 60% in the group with previous vertebral fractures. However, therapy did not significantly lower the hip fracture risk in women 80 years of age and older who had risk factors for falling but who did not have BMD testing performed to confirm osteoporosis.

In a randomized controlled trial of 265 postmenopausal women (mean age, 72 years), the incidence of vertebral fractures in women treated with risedronate 5 mg/day was significantly reduced during years 4 and 5 compared with placebo,¹⁷¹ and appeared to remain reduced through 7 years of treatment (no placebo group after 5 years).¹⁶⁸ No new adverse events were observed in these trials.

Ibandronate

Ibandronate, marketed as Boniva, is approved at an oral tablet daily dose of 2.5 mg as well as in a once-monthly oral tablet dose of 150 mg for the prevention and treatment of postmenopausal osteoporosis. It is also approved in an IV formulation at a dose of 3 mg every 3 months (administered by a healthcare professional) for the treatment of postmenopausal osteoporosis.

In early postmenopausal women (mean ages, 57.6-58.8 years) without osteoporosis, those receiving oral ibandronate at 2.5 mg/day had significant BMD increases of 1.9% in the lumbar spine (vs -1.9% for placebo) and 1.2% in the total hip (vs -0.6% for placebo) after 2 years.¹⁷² In older women (mean age, 69 years) with low spinal BMD and prevalent vertebral fractures, oral ibandronate at 2.5 mg/day significantly increased BMD compared with placebo in the spine (5.2%) and femoral neck (4.1%) after 3 years.¹⁷³ Daily oral ibandronate

therapy reduced morphometric vertebral fractures by 52% over the 3 years, but there was no significant effect on nonvertebral fracture risk in the overall study population. In a post hoc analysis, a 69% reduction of nonvertebral fracture risk was described, but only in the subgroup of study patients with baseline femoral neck T-scores below -3 .

Etidronate

The bisphosphonate etidronate, marketed as Didronel oral tablets, is approved in Canada for osteoporosis prevention and treatment in postmenopausal women. In the United States, it is approved only for treatment of Paget's disease, not for osteoporosis therapy.

A meta-analysis¹⁷⁴ of 13 trials investigating intermittent cyclic etidronate therapy for postmenopausal osteoporosis found that, relative to control groups, 1 to 3 years of therapy increased BMD by 4.1% in the lumbar spine and 2.3% in the femoral neck. This analysis concluded that etidronate significantly reduced the risk of vertebral fracture (37%) but not the risk of nonvertebral fracture.

For osteoporosis therapy, etidronate is typically administered at 400 mg/day for 14 days every 3 months, with calcium taken between the cycles. A cyclic regimen is used because daily high-dose use may interfere with bone mineralization.¹⁷⁵ This is not the schedule for Paget's disease.

Adverse events with bisphosphonate therapy

Bisphosphonates may cause upper GI disorders such as dysphagia, esophagitis, and esophageal and gastric ulcer, a contraindication in those with esophageal abnormalities that delay esophageal emptying or in those who are unable to stand or sit upright for at least 30 to 60 minutes after ingestion. Studies are not adequate to determine upper GI adverse effect differences among oral bisphosphonates, although once-quarterly IV ibandronate labeling does not carry the warnings of the tablet formulations regarding upper GI adverse events.

IV ibandronate labeling includes an enhanced precaution on hypocalcemia and renal impairment; however, no cases of acute renal failure have been observed in clinical trials. Patients who receive IV ibandronate should have serum creatinine measured before each dose administration.

Bisphosphonates are poorly absorbed; typically, approximately 0.5% of an oral dose is absorbed, even when taken on an empty stomach with plain water.

Therefore, oral bisphosphonates must be taken the first thing in the morning when the stomach is empty. Food, drink, and medications (including supplements) must be avoided for 30 minutes (alendronate and risedronate) to 60 minutes (ibandronate) after dosing; etidronate labeling recommends waiting 2 hours.

A transient flu-like illness, often called an acute-phase reaction, occurs infrequently with large doses of oral or IV bisphosphonates. This has been observed infrequently after monthly oral or quarterly IV dosing with ibandronate. Symptoms are generally mild, most often occur with the first, but not subsequent, doses and are treated symptomatically.

A theoretical concern exists regarding possible oversuppression of bone turnover with long-term bisphosphonate therapy, resulting in a more brittle skeleton. Individual cases with poor fracture healing after alendronate therapy have been described,¹⁷⁶ but most of those patients were receiving combined alendronate-estrogen therapy or had serious underlying medical problems.

Jaw lesions, usually after dental extraction (often described as osteonecrosis of the jaw), have been observed with bisphosphonate use, most often in patients treated with large intravenous doses for cancer-related bone diseases.^{177,178} The large dose amount, not the duration of therapy (12-25 months), was linked to the osteonecrosis. In 2- to 10-year randomized clinical trials of alendronate or risedronate using smaller oral doses appropriate for osteoporosis, no osteonecrosis of the jaw has been observed, although these lesions have been anecdotally reported.^{179,180}

Long-term safety of bisphosphonate therapy

Randomized clinical trials of more than 5 years' duration with alendronate or risedronate^{161,163,164,168} have demonstrated persistent reduction of bone turnover without evidence of unexpected adverse effects or abnormal bone histomorphometry. No data are available on effects of long-term (>3 years) ibandronate or etidronate therapy. Current evidence does not support recommendations regarding the optimal duration of bisphosphonate therapy.

Discontinuation of bisphosphonate therapy

Following discontinuation of alendronate after 4 to 5 years of therapy, bone turnover remains relatively suppressed with BMD remaining stable or decreasing slowly.^{163,164,181} Bone turnover markers remain

suppressed but return to pretreatment levels over time. Whether the fracture protection afforded by alendronate therapy persists after discontinuation is not known, although there is no apparent abrupt increase in fracture rate upon treatment cessation.

Discontinuation of risedronate therapy after 2 years in young postmenopausal women (mean ages, 51-52 years) has been shown to result in significant bone loss at both the spine and hip during the first year after treatment is stopped.¹⁶⁷ The effects of stopping therapy in older women or after longer treatment intervals are not known.

No data are available regarding discontinuation of ibandronate or etidronate therapy.

SERMs

The SERMs are nonsteroidal agents of various chemical structures that act as estrogen receptor agonists and/or antagonists. The SERM raloxifene (marketed as Evista oral tablets) is government approved for the prevention and treatment of osteoporosis at a dose of 60 mg/day. No other SERM is approved for osteoporosis therapy, although several are in clinical development.

Raloxifene has beneficial effects on BMD, and it decreases bone turnover as assessed by biochemical markers. In a 2-year randomized controlled trial of 601 postmenopausal women without osteoporosis (mean age, 55 years), raloxifene at a dose of 60 mg/day significantly improved BMD at the lumbar spine (1.6%) and femoral neck (1.2%) compared with placebo (decreases of 0.8% and 1.2%, respectively).¹⁸² In the randomized controlled Multiple Outcomes of Raloxifene Evaluation (MORE) trial evaluating postmenopausal women with osteoporosis (mean age, 67 years),¹⁸³ 3 years of raloxifene therapy at 60 mg/day significantly increased BMD versus placebo by 2.6% at the spine and 2.1% at the femoral neck.

The efficacy of raloxifene in reducing osteoporotic fractures also was demonstrated in the MORE trial.¹⁸³ After 3 years of therapy, raloxifene (60 mg/day) reduced the risk of vertebral fracture by 55% in women with a femoral neck or lumbar spine BMD T-score of -2.5 or below and by 30% in women with low T-scores and a prevalent vertebral fracture; both findings were significant compared with placebo. A 1-year blinded extension of the MORE trial¹⁸⁴ found persistent vertebral fracture risk reductions of 50% and 38% in the two groups, respectively. A separate analysis revealed that at 1 year, raloxifene (60 mg/day) reduced the risk of new clinical vertebral fracture by 68% in the overall study population.¹⁸⁵

No raloxifene effect has been observed on hip or other nonvertebral fracture risk.

In addition to its effects on bone, raloxifene has been associated with a reduced risk of invasive breast cancer in postmenopausal women with osteoporosis. In the MORE trial, the overall incidence of invasive breast cancer was significantly reduced by 76% after 3 years¹⁸⁶ and 72% after 4 years.¹⁸⁷ In a 4-year extension of the MORE trial—the Continuing Outcomes Relevant to Evista (CORE) trial¹⁸⁸—the risk after 8 years was 59% lower in raloxifene recipients; the risk of estrogen receptor (ER)-positive invasive breast cancer was 66% lower. The combined results show invasive breast cancer and ER-positive breast cancer risks were reduced by 66% and 76%, respectively. It should be noted that the MORE-CORE studies were conducted on postmenopausal women initially selected for risk of osteoporosis, not for risk of breast cancer.

A significant increase in thromboembolic events was noted in the MORE trial.¹⁸⁹ However, a secondary analysis of the MORE trial data¹⁹⁰ found no overall significant differences in the number of coronary or cerebrovascular events between placebo and raloxifene, although in a subset of women with increased cardiovascular risk at baseline, raloxifene significantly reduced cardiovascular risk. Again, it should be noted that the MORE trial was not designed with cardiovascular outcomes as the primary objective.

Randomized clinical trials of more than 5 years' duration have demonstrated no other significant adverse effects.¹⁸⁹ Raloxifene therapy may be associated with an increase in vasomotor symptoms. However, it does not increase the risk of cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer or cause vaginal bleeding or breast pain.^{183,189}

Bone loss often resumes when raloxifene therapy is stopped.^{191,192}

Parathyroid hormone

The various chemical structures of parathyroid hormone (PTH) are anabolic agents that directly stimulate osteoblastic bone formation, resulting in substantial increases in trabecular bone density and connectivity in women with postmenopausal osteoporosis. This mechanism of action is very different from that of antiresorptive agents such as estrogen and bisphosphonates, which reduce bone resorption.

Teriparatide (recombinant human PTH 1-34), marketed as Forteo, is approved in both the United States and Canada for the treatment of postmenopausal

women with osteoporosis who are at high risk of fracture. A full-length PTH (1-84) is being evaluated in clinical trials.

Randomized controlled trials have shown that daily subcutaneous injections of teriparatide stimulate bone formation and improve bone density in postmenopausal women, regardless of whether they are receiving estrogen therapy.¹⁹³⁻¹⁹⁵ In postmenopausal women with previous vertebral fracture,¹⁹⁵ 19 months of teriparatide treatment (20 µg/day) significantly increased bone density in the spine by 8.6% and in the femoral neck by 3.5% compared with placebo. The incidence of new vertebral fractures was reduced by 65% and new nonvertebral fragility fractures by 53%, although the study was not designed to examine the effect on hip fractures.

Drug-related adverse effects include muscle cramps and infrequent hypercalcemia, nausea, and dizziness. High-dose teriparatide treatment has caused bone tumors (osteosarcoma) in a rat model at doses ranging from 3 to 60 times the 20 µg/day dose in humans,¹⁹⁶ although the significance of this finding in humans is uncertain. Teriparatide should not be administered to postmenopausal women with hypercalcemia, bone metastases, or disorders that predispose them to bone tumors such as Paget's disease or those who received prior skeletal irradiation. Therapy is indicated for no longer than 18 to 24 months.

When PTH therapy is stopped, substantial bone loss has occurred within the first year.¹⁹⁷ However, in randomized controlled trials using PTH 1-84, administering alendronate after discontinuing PTH therapy was shown to maintain or improve BMD,^{197,198} although previous alendronate treatment tends to slow bone turnover and delay the PTH-induced increases in BMD and bone turnover response by 3 to 6 months.¹⁹⁹ It is unclear whether a second course of PTH can be safely restarted after a period without therapy or whether regimens other than daily can be effective.

Estrogens

Systemic estrogen products (EPT or ET for women without a uterus) are government approved in the United States and Canada for prevention, but not treatment, of postmenopausal osteoporosis. A number of randomized controlled trials have evaluated the effect of systemic estrogen on BMD and fracture in postmenopausal women.

Bone mineral density

The beneficial effects of systemic oral or transdermal ET/EPT at standard doses on BMD preservation

are well established. A 2002 meta-analysis²⁰⁰ of 57 randomized clinical trials comparing ET/EPT with placebo in postmenopausal women found consistent BMD increases with ET/EPT at all sites. In trials of 2 years' duration, the mean difference in BMD after ET/EPT was 6.8% at the lumbar spine and 4.1% at the femoral neck.

The two largest and best controlled trials support these findings. In the Postmenopausal Estrogen/Progestin Interventions trial²⁰¹ (N = 875), standard daily doses of 0.625 mg conjugated equine estrogens (CEE), with or without a progestogen [either medroxyprogesterone acetate (MPA) or micronized progesterone], for 3 years significantly increased spinal BMD by 3.5% to 5.0%, with a 1.7% increase in hip BMD. More recently, the WHI,²⁰² a 5-year randomized controlled trial in postmenopausal women aged 50 to 79 years (N = 16,608), reported that standard doses of daily EPT (0.625 mg CEE plus 2.5 mg MPA) significantly increased spine and total hip BMD by 4.5% and 3.7%, respectively, relative to placebo.

Effects of lower-than-standard doses of ET/EPT on BMD have been investigated. Randomized controlled trials²⁰³⁻²⁰⁷ using doses as low as 0.3 mg/day oral CEE, 0.25 mg/day oral micronized 17β-estradiol, and 0.014 mg/day transdermal 17β-estradiol reported significant increases in spine and hip BMD relative to placebo. These trials were conducted either in populations of early postmenopausal women (mean age, 51-52 years) or in older postmenopausal women (mean ages, 67 and 74 years). Changes in lumbar spine BMD were in the range of 1% to 3%, significantly better than placebo.

Significant BMD improvements have also been noted with systemic estrogen doses delivered via a vaginal ring (Femring).²⁰⁸ In a randomized controlled trial of 174 postmenopausal women younger than age 65, daily doses of 0.05 and 0.1 mg of estradiol acetate delivered via the ring significantly increased hip BMD (1.7% and 1.8%, respectively) and lumbar spine BMD (2.7% and 3.3%) compared with baseline.

Fracture

Evidence from both randomized controlled trials and observational studies indicate that standard doses of ET/EPT (including 0.625 mg CEE/day or the equivalent) reduce fracture risk in postmenopausal women. Two meta-analyses have found that ET/EPT significantly reduces the risk of fracture by up to 27%.^{209,210}

Two recent, large observational studies support these data. The National Osteoporosis Risk Assessment

study examined 200,160 postmenopausal women and reported that current estrogen use was associated with a significantly reduced risk of new fracture.¹⁰² Participants were at least 50 years old and had no previous diagnosis of osteoporosis. The Million Women Study,²¹¹ a prospective observational study of 138,737 postmenopausal women, reported that current ET/EPT use provided a significant relative risk reduction in incidence of fracture.

Results were confirmed in the WHI. In both the EPT arm²⁰² and the ET arm,²¹² significant risk reductions were seen for hip fractures, vertebral fractures, and total fractures compared with placebo. The selection criteria and outcomes evaluated in the WHI (ie, women were not selected based on an established osteoporosis risk factor or BMD level; fracture outcomes included hip, wrist/lower arm, and clinically identified vertebral and total fractures) are in contrast to the design of studies of fracture risk reduction with bisphosphonates or SERMs.^{36,163,166,169,170,183} In those studies, women were selected based on high risk of osteoporosis (ie, prevalent vertebral fracture and/or low BMD), and radiographically detected vertebral fractures were often a primary outcome.

The Million Women Study, although observational in design, addressed issues related to ET/EPT and the risk of fracture that could not be ascertained in the WHI trials, such as comparisons between different EPT formulations, doses, and routes of administration. When the overall fracture-risk reduction was examined by type of hormone, no difference was found between ET and EPT. Sequential or continuous progestin use also did not significantly affect the results. Furthermore, the relative risk of fracture was not different when specific estrogen or progestin products were compared (ie, CEE versus estradiol; MPA versus norethisterone or norgestrel/levonorgestrel). This study did not specifically report on the possible fracture protection afforded by a low estrogen dose (ie, 0.3 mg), but found that similar risk reductions for doses greater than 0.625 mg were similar to those for doses 0.625 mg or less.

Therapy management

The primary indication for systemic ET/EPT is for women experiencing moderate to severe menopause symptoms (eg, vasomotor symptoms, vaginal atrophy).

In the WHI, systemic EPT (CEE plus MPA) at standard doses for 5.6 years in postmenopausal women aged 50 to 79 years was associated with a statistically significant increased risk of breast cancer,²¹³ stroke,²¹⁴

coronary heart disease,²¹⁵ and thromboembolic event.²¹⁶ In women who had undergone a hysterectomy, ET alone for 6.8 years resulted in a statistically significant increased risk of stroke and deep venous thrombosis, whereas total venous thromboembolic events and pulmonary embolism were not statistically increased.²¹² For postmenopausal women aged 65 to 79 years followed for a mean of 4.0 years, the Women's Health Initiative Memory Study²¹⁷ found a statistically significant increase in probable dementia for those who started EPT (CEE plus MPA). After a mean follow-up of 5.2 years, there was a nonsignificant trend for increased probable dementia among women allocated to ET alone.

NAMS recommends use of ET/EPT at the lowest effective dose for the shortest time period consistent with treatment goals.²¹⁸ Lower-than-standard doses of ET/EPT, however, have not been examined with regard to fracture efficacy. Specific to the use of ET/EPT for its effects on osteoporosis, NAMS states that systemic ET/EPT can still be considered, weighing its risks and benefits as well as those of alternate therapies. The optimal time to initiate ET/EPT and the optimal duration of therapy have not been established.

Discontinuation of therapy

Studies have shown a BMD loss of 3% to 6% during the first year after cessation of systemic ET/EPT.^{181,219-222} Data also indicate that the fracture risk reduction with ET/EPT use does not persist after discontinuation of therapy. In the Million Women Study,²¹⁰ past users of hormone therapy had no protection against fracture, and incidence rates returned to those of never-users within about 1 year of ceasing use. In the National Osteoporosis Risk Assessment study,²²³ clinical fractures of the hip, spine, forearm, wrist, or rib were reduced in current ET/EPT users but not in women who had stopped 5 years previously. In a further analysis of hip fractures, women who had discontinued ET/EPT within the previous 5 years had a risk of hip fracture at least as high as that in women who had never used ET/EPT.²²⁴

Calcitonin

Salmon calcitonin is government approved for postmenopausal osteoporosis treatment but not for prevention.²²⁵ It is available in the United States as a nasal spray (marketed as Miacalcin Nasal Spray, Fortical Nasal Spray) and a subcutaneous injection (marketed as Miacalcin Injection). Available in Canada are a nasal spray (Miacalcin Nasal Spray)

and an injectable form (marketed as Calcimar Solution, Caltine), although these injectables are not indicated for osteoporosis.

Calcitonin is an inhibitor of bone resorption. In clinical use, however, the reduction in bone turnover with calcitonin is much less than with other antiresorptive agents. A small, dose-finding study of intranasal calcitonin in postmenopausal women with osteoporosis showed significant increases in spinal BMD of 3% relative to baseline.²²⁶

In the randomized controlled Prevent Recurrence of Osteoporotic Fractures (PROOF) trial,²²⁷ intranasal spray calcitonin doses of 200 IU/day for 5 years significantly reduced the risk of new vertebral fracture by 33% compared with placebo in 1,255 postmenopausal women with established osteoporosis. However, statistically significant reductions were not observed at either 100 IU/day or 400 IU/day. After 5 years, a significant spinal BMD increase compared with placebo was seen only for recipients of the 400-IU dose. No significant effect on hip BMD occurred at any dose. The absence of a dose response and a 60% dropout rate have led some experts to doubt the reliability of these data.

Calcitonin has been shown to reduce bone pain from osteoporotic vertebral compression fractures more quickly than placebo immediately after a fracture;^{228,229} however, it has not been shown to decrease bone pain in other situations.²³⁰ Drug-related adverse effects include nausea, local inflammation, and flushing of the face or hands when given as an injection and local nasal irritation with the nasal spray formulation.

Because calcitonin is a less potent agent than other pharmacologic therapies for osteoporosis, it is reserved as an alternative for women who cannot or choose not to take one of the other osteoporosis agents. The efficacy of calcitonin has not been observed in early postmenopausal women. Thus, product labeling recommends its use only in women with osteoporosis who are at least 5 years beyond menopause.

Combination therapies

Combining potent antiresorptive agents results in small additional increments in bone density. In postmenopausal women (mean age, 61-62 years) with low bone mass, BMD improvements in the spine and hip with combined alendronate and ET were significantly greater (8.3%) than results for either agent alone (6.0%).²³¹ Combined risedronate and ET/EPT also has shown favorable, although modest, BMD effects compared with either agent alone.²³² Whether

increases in BMD result in better fracture protection is not known, and the long-term safety of combination therapies has not been evaluated. One concern is that combining two antiresorptive therapies might oversuppress bone turnover, adversely affect bone quality, and thereby increase the likelihood of fracture. Combining antiresorptive agents is not generally recommended.

Combining an anabolic agent such as teriparatide with an antiresorptive agent has been considered. Significant increases in BMD occurred in a randomized controlled trial when teriparatide was added to ongoing ET.¹⁹⁴ When PTH 1-84 and alendronate were combined, the BMD response was less than that seen with PTH alone.¹⁹⁷ Based on available data, recommendations cannot be made for or against combining antiresorptive and anabolic drugs.

Promising new therapies

Several new drugs show promise for the treatment and/or prevention of osteoporosis. Some are now available outside North America, while others are in clinical development. These include another IV bisphosphonate (zoledronic acid), additional SERMs (lasofoxifene, arzoxifene, and basodoxifene), PTH 1-84, tibolone, denosumab, and strontium ranelate. Although some data on statins and thiazides suggest beneficial bone effects, it is unlikely that randomized controlled trials will be performed to evaluate potential benefits.

This document summarizes data for the only promising therapy that has demonstrated fracture efficacy in published trials, oral strontium ranelate. Approved for the prevention and treatment of osteoporosis in more than 25 countries outside North America, strontium ranelate (marketed as Protelos), appears to have modest antiresorptive and mild anabolic effects, although its mechanism of action is unknown. Dosing involves dissolving 2 g of strontium ranelate in water and drinking it before bedtime.

Efficacy is best documented by fracture trials. BMD may show artifactual increases due to the higher molecular weight of strontium compared with the calcium it replaces in the skeleton.

In large randomized controlled trials in postmenopausal women in Europe and Australia,^{233,234} 3 years of strontium therapy significantly increased bone density and reduced the incidence of both spine and nonspine fractures. Drug-related adverse effects included significant increases in nausea and diarrhea that resolved after 3 months. Increases in bone formation markers (less than seen with PTH) and

decreases in bone resorption markers (less than with bisphosphonates or estrogen) have been observed with strontium therapy.

A large randomized controlled trial in postmenopausal women with the primary end point of vertebral fractures²³³ demonstrated that 3 years of therapy significantly increased bone density at the spine (14%) and femoral neck (8%). Compared with placebo, the risk of spine fractures in strontium-treated women was significantly reduced by 49% after 1 year and 41% after 3 years compared with placebo. A second randomized controlled trial investigating nonvertebral fractures²³⁴ reported that after 3 years, nonvertebral fractures were significantly reduced by 16% in treated women compared with placebo. In a subgroup of high-risk women (older than age 74 with a femoral neck T-score of less than -2.4), there was a 36% decrease in hip fractures. Drug-related adverse effects in both trials were infrequent and included nausea and diarrhea that usually resolved after 3 months.

RECOMMENDATIONS

Management strategies for osteoporosis in postmenopausal women require assessment of risk factors for BMD-defined osteoporosis and osteoporotic fracture, followed by institution of measures that focus on reducing risk factors through lifestyle changes and, if indicated, pharmacologic therapy.

- All postmenopausal women should be encouraged to employ lifestyle practices that reduce the risk of bone loss and osteoporotic fractures: maintaining a healthy weight, eating a balanced diet, obtaining adequate calcium and vitamin D, participating in appropriate exercise, avoiding excessive alcohol consumption, not smoking, and using measures to prevent falls. Periodic reviews of calcium and vitamin D intake and lifestyle behaviors are useful. After menopause, a woman's risk of falls should be assessed at least annually.
- The physical examination should include an annual measurement of height and weight, along with an assessment for kyphosis and back pain.
- BMD testing is indicated for:
 - All postmenopausal women with medical causes of bone loss
 - All postmenopausal women aged 65 and older
 BMD testing should be considered for healthy postmenopausal women younger than age 65

who have one or more of the following risk factors:

- Previous fracture (other than skull, facial bone, ankle, finger, and toe) after menopause
- Thinness [body weight <127 lb (57.7 kg) or BMI <21 kg/m²]
- History of hip fracture in a parent
- Current smoking

When BMD testing is indicated, DXA is the preferred technique. The total hip, femoral neck, and posterior-anterior lumbar spine should be measured, using the lowest of the three BMD scores.

- The routine use of biochemical markers of bone turnover in clinical practice is not generally recommended.
- If osteoporosis is diagnosed, either clinically or by BMD, any secondary causes should be identified, although the data defining the most thorough or cost-effective workup are limited.
- Vertebral fracture must be confirmed, through either a vertebral fracture assessment with DXA measurement of the spine or height loss of more than 20% (or 4 mm) of a vertebra on spinal radiograph.
- In postmenopausal women, the need for prescription osteoporosis therapy is based on a combination of BMD and risk factors. Osteoporosis drug therapy is recommended in the following populations:
 - All postmenopausal women who have had an osteoporotic vertebral fracture
 - All postmenopausal women who have BMD values consistent with osteoporosis (ie, T-score worse than or equal to -2.5)
 - All postmenopausal women who have a T-score from -2.0 to -2.5 plus at least one of the following risk factors for fracture: thinness, history of fragility fracture (other than skull, facial bone, ankle, finger, and toe) since menopause, and history of hip fracture in a parent
- Treatment recommendations are based on both efficacy data and clinical parameters, which include magnitude of fracture risk, side effect profile, tolerability of specific drugs, extraskelatal risks and potential benefits, confounding diseases, cost, and patient preference, including choice of dosing. Selection of one therapy over another cannot be made on the basis of clinical evidence because head-to-head trials comparing the effectiveness of pharmacologic therapies to reduce fracture risk have not been conducted.
- Bisphosphonates are the first-line drugs for treating postmenopausal women with osteoporosis. Alendronate and risedronate reduce the risk of

- both vertebral and nonvertebral fractures. Whether there are differences in fracture protection among the bisphosphonates is uncertain. It is likely that all produce greater relative and absolute fracture risk reductions in women with more severe osteoporosis.
- The SERM raloxifene is most often considered in postmenopausal women with low bone mass or younger postmenopausal women with osteoporosis who are at greater risk of spine fracture than hip fracture. It prevents bone loss and reduces the risk of vertebral fractures, but its effectiveness in reducing other fractures is uncertain. Extraskel-etal risks and benefits are important when considering raloxifene therapy.
 - Teriparatide (PTH 1–34) is reserved for treating women at high risk of fracture, including those with very low BMD (T-score worse than –3.0) with a previous vertebral fracture. PTH improves BMD and reduces the risk of new vertebral and nonvertebral fractures. Dosage requirements (ie, daily subcutaneous injections) may limit use.
 - The primary indication for systemic ET/EPT is to treat moderate to severe menopause symptoms (eg, vasomotor symptoms). When symptoms are controlled or cease, continued hormone therapy can still be considered for bone effects, weighing its benefits and risks against those of alternate therapies.
 - Calcitonin is not a first-line drug for postmenopausal osteoporosis treatment, as its fracture efficacy is not strong and its BMD effects are less than those of other agents. However, it is an option for women with osteoporosis who are more than 5 years beyond menopause. Calcitonin therapy may reduce vertebral fracture risk in women with osteoporosis, although the evidence documenting fracture protection is not strong. It is not recommended for treating bone pain, except bone pain from acute vertebral compression fractures.
 - Data are inadequate to make definitive recommendations regarding combination or serial antiresorptive and anabolic drug therapy.
 - During therapy, it is appropriate to reevaluate the treatment goals and the choice of medication on an ongoing basis through periodic medical examination and follow-up BMD testing. Measurement of BMD has limited use in predicting the effectiveness of antiresorptive therapies for reducing fracture risk. Also, fracture risk reductions from therapy occur much more rapidly than bone density changes. An appropriate interval for repeat BMD testing is 2 years.
 - It is important to encourage adherence to the treatment plan and to identify barriers to non-adherence. Providing clear information to women regarding their risk of fracture and the purpose of osteoporosis therapy may be the optimal way to improve adherence.
 - If drug-related adverse effects occur, appropriate management strategies should be instituted. If adverse effects persist, switching to another agent may be required.
 - The treatment of osteoporosis needs to be long term in most women.
 - Decisions to discontinue or suspend therapy are based on the woman's risk of fracture and her response to treatment, as well as the likelihood of diminishing beneficial effects from the agent used. Given the uncertainties of long-term safety, careful monitoring is required. Fracture risk after discontinuing therapy has not been adequately evaluated.

Acknowledgments: NAMS appreciates the contributions of the following members of the Editorial Board: *Bruce Ettinger, MD*, Clinical Professor of Medicine, University of California, San Francisco, CA; *Steven T. Harris, MD, FACP*, Clinical Professor of Medicine, University of California, San Francisco, CA; *David Kendler, MD*, Assistant Professor, University of British Columbia, Vancouver, BC, Canada; *Bruce Kessel, MD*, Associate Professor, Department of Obstetrics and Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI; and *Michael R. McClung, MD*, Director, Oregon Osteoporosis Center, Portland, OR.

Final review and approval was conducted by the 2005–2006 NAMS Board of Trustees: *George I. Gorodeski, MD, PhD* (President), Professor of Reproductive Biology, Oncology, and Physiology and Biophysics, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Department of Obstetrics and Gynecology, Cleveland, OH; *Marilyn L. Rothert, PhD, RN, FAAN* (President-Elect), Dean and Professor, College of Nursing, Michigan State University, East Lansing, MI; *Victor W. Henderson, MD, MS* (Treasurer), Professor, Departments of Health Research & Policy and Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA; *Marcie K. Richardson, MD* (Secretary), Assistant Director of Obstetrics and Gynecology for Clinical Quality, Harvard Vanguard Medical Associates, Boston, MA; *Robert R. Freedman, PhD*, Professor, Departments of Psychiatry and Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI; *J. Chris Gallagher, MD*, Professor of Medicine, Creighton University Medical School, Department of Metabolism, St. Joseph's Hospital, Omaha, NE; *Steven R. Goldstein, MD*, Professor of Obstetrics and Gynecology, New York University School of Medicine, New York, NY; *Bruce Kessel, MD*, Associate Professor, Department of Obstetrics and Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI; *JoAnn V.*

Pinkerton, MD, Professor, Department of Obstetrics and Gynecology, Medical Director, The Women's Place, Midlife Health Center, University of Virginia Health Sciences Center, Charlottesville, VA; *Nancy K. Reame, MSN, PhD, FAAN*, Mary Dickey Lindsay Professor of Nursing and Director, DNSc Program, Columbia University School of Nursing, New York, NY; *Leon Speroff, MD*, Professor of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR; *Cynthia A. Stuenkel, MD*, Clinical Professor of Medicine, University of California, San Diego, La Jolla, CA; *Isaac Schiff, MD (Ex Officio)*, Joe Vincent Meigs Professor of Gynecology, Harvard Medical School, Chief, Vincent Memorial Obstetrics and Gynecology Service, Massachusetts General Hospital, Women's Care Division, Boston, MA; and *Wulf H. Utian, MD, PhD (Ex Officio)*, Arthur H. Bill Professor Emeritus of Reproductive Biology, Case Western Reserve University School of Medicine, Consultant in Obstetrics and Gynecology, The Cleveland Clinic Foundation, Executive Director, The North American Menopause Society, Cleveland, OH.

The Society also acknowledges the contributions of *Ian D. Graham, PhD*, Senior Social Scientist and Associate Director, Clinical Epidemiology Program, Ottawa Health Research Institute, University of Ottawa, ON, Canada; as well as *Philip K. Lammers*, former NAMS Medical Editor, and *Pamela P. Boggs, MBA*, NAMS Director of Education and Development.

DISCLOSURE

NAMS is committed to ensuring balance, independence, and objectivity in all its educational activities. All those involved in the development of a CME activity are required to disclose financial relationships they or their spouse/partner have had during the past 12 months with a commercial interest whose products or services are discussed in the CME activity content, or with any commercial supporters of the activity over which they have control.

For the Editorial Board, Dr. Ettinger reports Berlex, GlaxoSmithKline, Novartis, Merck, Procter & Gamble, Roche, (consultant); Dr. Harris reports Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Procter & Gamble, Roche, sanofi-aventis, Wyeth (consultant); Eli Lilly, GlaxoSmithKline, Merck, Procter & Gamble, Roche, sanofi-aventis, Wyeth (sponsored lectures); Dr. Kendler reports Amgen, Eli Lilly, Merck, Novartis, Pfizer, Servier, Wyeth (consultant, research support, speakers' bureau); Dr. Kessel reports Procter & Gamble, Wyeth (research support), Berlex, Procter & Gamble, Merck, Wyeth (speakers' bureau); Dr. McClung reports Wyeth (consultant), Amgen, Eli Lilly, Merck, Novartis, Pfizer, sanofi-aventis (consultant, research support).

For the NAMS Board of Trustees who are not serving on the Editorial Board, Dr. Freedman reports Alexza, Duramed, GlaxoSmithKline, Novartis, Organon, Pfizer, Vela, Wyeth (consultant), GlaxoSmithKline, National Institutes of Health, Organon (research support); Dr. Gallagher reports GlaxoSmithKline, Organon, Pfizer, Wyeth (consultant), Organon, Pfizer, Wyeth (research support); Dr. Goldstein reports Eli Lilly, Merck, Pfizer, Procter & Gamble, TAP (advisory boards); Dr. Gorodeski reports Molecular Diagnostics (advisory board); Dr. Henderson reports Council on Hormone Education (consultant); Dr. Pilkerton reports Duramed, Eli Lilly, Merck, Procter & Gamble, Roche, Solvay (consultant), Berlex, Eli Lilly, Pfizer/Alta, Procter & Gamble, Wyeth (speakers' bureau),

Eli Lilly, Merck, Pfizer, Procter & Gamble, Solvay, Wyeth (research support), Council on Hormone Education (executive committee); Dr. Reame reports Procter & Gamble (consultant), Novo Nordisk, Procter & Gamble (research support); Dr. Rothert reports no significant financial relationships; Dr. Richardson reports Procter & Gamble (consultant); Dr. Schiff reports Alliance for Better Bone Health, Medco, *Pause*, the consumer magazine of the American College of Obstetricians and Gynecologists (advisory board), *Menopause*, the official journal of The North American Menopause Society (editor-in-chief); Dr. Speroff reports Barr (consultant), Berlex, Organon, Wyeth (research support); Dr. Stuenkel reports no significant financial relationships; Dr. Utian reports Barr/Duramed, Berlex, Johnson & Johnson Pharmaceutical Research and Development, Merck, Merriam, Novartis, Organon, Pfizer, Roche/GlaxoSmithKline (consultant, advisory board), Amylin, 3M, Barr, Berlex, Bristol-Myers Squibb, Duramed, Eli Lilly, Forest, Glen, GlaxoSmithKline, Johnson & Johnson, Neurocrine Biosciences, Novartis, Novo Nordisk, Organon, Pharmacia, Procter & Gamble, Pfizer, Roche, Sepracor, Solvay, Wyeth, Yamanouchi (research support). For additional contributors, Ms. Boggs, Dr. Graham, and Mr. Lammers all report no significant financial relationships.

REFERENCES

1. The North American Menopause Society. Management of postmenopausal osteoporosis. *Menopause* 2002;9:84-101.
2. Guyatt GH, Sackett DL, Sinclair JC, et al. Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. *JAMA* 1995;274:1800-1805.
3. Jackson R, Feder G. Guidelines for clinical guidelines [Editorial]. *BMJ* 1998;317:427-428.
4. Scottish Intercollegiate Guidelines Network. SIGN guidelines: an introduction to SIGN methodology for the development of evidence-based clinical guidelines. Available at: <http://www.sign.ac.uk>. Accessed October 30, 2005.
5. Boggs P, Utian W. The North American Menopause Society develops consensus opinions [Editorial]. *Menopause* 1998;5: 67-68.
6. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA* 2001;85:785-795.
7. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. *Osteoporos Int* 1994;4:368-381.
8. Bonjour JP, Theintz G, Law F, Slosman D, Rizzoli R. Peak bone mass. *Osteoporos Int* 1994;4(Suppl 1):S7-S13.
9. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. *Osteoporos Int* 1998;8:468-489.
10. Eastell R. Forearm fracture. *Bone* 1996;18(Suppl 3):S203-S207.
11. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. *J Bone Miner Res* 1997;12:1761-1768.
12. Melton LJ III, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. *J Bone Miner Res* 1997;12:16-23.
13. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. *Arch Intern Med* 2004;164:1108-1112.
14. Stone KL, Seeley DG, Lui LY, et al. for the Study of Osteoporotic Fractures. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. *J Bone Miner Res* 2003;18:1947-1954.

15. Wainwright SA, Marshall LM, Ensrud KE, et al, for the Study of Osteoporotic Fracture Research Group. Hip fracture in women without osteoporosis. *J Clin Endocrinol Metab* 2005;90:2787-2793.
16. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. *Osteoporos Int* 2005;16(Suppl 2):S3-S7.
17. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? *J Bone Miner Res* 1992;7:1005-1010.
18. Barrett-Connor E, Wehren LE, Siris ES, et al. Osteoporosis and fracture risk in women of different ethnic groups. *J Bone Miner Res* 2005;20:185-194.
19. Cauley JA, Lui LY, Ensrud KE, et al. Bone mineral density and the risk of incident nonspinal fractures in black and white women. *JAMA* 2005;293:2102-2108.
20. US Congress Office of Technology Assessment. *Hip Fracture Outcomes in People Age 50 and Over—Background Paper*. Publication OTA-BP-H-120. Washington, DC: US Government Printing Office, 1994.
21. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. *JAMA* 2001;285:320-323.
22. Klotzbuecher CM, Ros PD, Landsman PB, Abbott TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res* 2000;15:721-739.
23. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, for the Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. *Arthritis Rheum* 2001;44:2611-2619.
24. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. *Osteoporos Int* 2000;11:556-561.
25. Gold DT. The nonskeletal consequences of osteoporotic fractures: physiologic and social outcomes. *Rheum Dis Clin North Am* 2001;27:255-262.
26. Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. *J Bone Miner Res* 1998;13:763-773.
27. Johnell O, Gullberg B, Kanis JA, et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. *J Bone Miner Res* 1995;10:1802-1815.
28. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures: the Study of Osteoporotic Fractures Research Group. *Lancet* 1993;341:72-75.
29. Kanis JA, Gluer CC, for the Committee of Scientific Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. *Osteoporos Int* 2000;11:192-202.
30. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996;312:1254-1259.
31. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. *Osteoporos Int* 2001;12:989-995.
32. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. *Bone* 2004;34:599-604.
33. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis: Fracture Intervention Trial Research Group. *Arthritis Rheum* 1999;42:1246-1254.
34. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. *J Clin Densitom* 2004;7:255-261.
35. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. *Curr Med Res Opin* 2004;20:433-439.
36. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. *JAMA* 1999;282:1344-1352.
37. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. *Bone* 2004;35:1029-1037.
38. Slemenda CW, Christian JC, Williams CJ, et al. Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. *J Bone Miner Res* 1991;6:561-567.
39. Pocock NA, Eisman JA, Hopper JL, et al. Genetic determinants of bone mass in adults: a twin study. *J Clin Invest* 1987;80:706-710.
40. Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women: the Study of Osteoporotic Fractures Research Group. *Ann Intern Med* 1993;118:657-665.
41. Seeman E, Hopper JL, Bach LA, et al. Reduced bone mass in daughters of women with osteoporosis. *N Engl J Med* 1989;320:554-558.
42. Evans RA, Marel GM, Lancaster EK, et al. Bone mass is low in relatives of osteoporotic patients. *Ann Intern Med* 1988;109:870-873.
43. Kanis JA, De Laet C, Delmas P, et al. A meta-analysis of previous fracture and fracture risk. *Bone* 2004;35:375-382.
44. Nieves JW, Golden AL, Siris E, Kelsey JL, Lindsay R. Teenage and current calcium intake are related to bone mineral density of the hip and forearm in women aged 30-39 years. *Am J Epidemiol* 1995;141:342-351.
45. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. *Endocr Rev* 2001;22:477-501.
46. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. *N Engl J Med* 1992;327:1637-1642.
47. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. *N Engl J Med* 1997;337:670-676.
48. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 2003;326:469-475.
49. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* 2005;293:2257-2264.
50. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. *BMJ* 2005;330:1003-1009.
51. Grant AM, Avenell A, Campbell MK, et al, for the RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* 2005;365:1621-1628.
52. Holbrook TL, Barrett-Connor E, Wingard DL. Dietary calcium and risk of hip fracture: 14-year prospective population study. *Lancet* 1988;2:1046-1049.
53. Basseij EJ, Ramsdale SJ. Increase in femoral bone density in young women following high-impact exercise. *Osteoporos Int* 1994;4:72-75.

54. Taaffe DR, Robinson TL, Snow CM, Marcus R. High-impact exercise promotes bone gain in well-trained female athletes. *J Bone Miner Res* 1997;12:255-260.
55. Welsh L, Rutherford OM. Hip bone mineral density is improved by high-impact aerobic exercise in postmenopausal women and men over 50 years. *Eur J Appl Physiol Occup Physiol* 1996;74:511-517.
56. Gutin B, Kasper JM. Can vigorous exercise play a role in osteoporosis prevention? A review. *Osteoporos Int* 1992;2:55-69.
57. Globus RK, Bikle DD, Morey-Holton E. The temporal response of bone to unloading. *Endocrinology* 1986;118:733-742.
58. Prince RL, Price RI, Ho S. Forearm bone loss in hemiplegia: a model for the path of immobilization osteoporosis. *J Bone Miner Res* 1988;3:305-310.
59. Slemenda CW, Hui SL, Longcope C, et al. Cigarette smoking, obesity, and bone mass. *J Bone Miner Res* 1989;4:737-741.
60. Kato I, Toniolo P, Akhmedkhanov A, et al. Prospective study of factors influencing the onset of natural menopause. *J Clin Epidemiol* 1998;51:1271-1276.
61. Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. *J Bone Miner Res* 1991;6:331-338.
62. Baron JA, Farahmand BY, Weiderpass E, et al. Cigarette smoking, alcohol consumption, and risk for hip fracture in women. *Arch Intern Med* 2001;161:983-988.
63. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. *Osteoporos Int* 2005;16:155-162.
64. Rapuri PB, Gallagher JC, Balhorn KE, Ryschon KL. Smoking and bone metabolism in elderly women. *Bone* 2000;27:429-436.
65. Krall EA, Dawson-Hughes B. Smoking increases bone loss and decreases intestinal calcium absorption. *J Bone Miner Res* 1999;14:215-220.
66. Jensen J, Christiansen C, Rodbro P. Cigarette smoking, serum estrogens and bone loss during hormone replacement therapy early after menopause. *N Engl J Med* 1985;313:973-975.
67. Felson DT, Zhang Y, Hannan MT, Kannel WB, Kiel DP. Alcohol intake and bone mineral density in elderly men and women: the Framingham Study. *Am J Epidemiol* 1995;142:485-492.
68. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. *Osteoporos Int* 2005;16:737-742.
69. Rapuri PB, Gallagher JC, Balhorn KE, Ryschon KL. Alcohol intake and bone metabolism in elderly women. *Am J Clin Nutr* 2000;72:1206-1213.
70. Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures: the Framingham Study. *Am J Epidemiol* 1988;128:1102-1110.
71. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. *N Engl J Med* 1995;332:767-773.
72. van der Voort DJ, Geusens PP, Dinant GJ. Risk factors for osteoporosis related to their outcome: fractures. *Osteoporos Int* 2001;12:630-638.
73. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. *Osteoporos Int* 2005;16:1330-1338.
74. Recker RR, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. *J Bone Miner Res* 2000;15:1965-1973.
75. Pouilles JM, Tremollieres F, Ribot C. Vertebral bone loss in perimenopause: results of a 7-year longitudinal study. *Presse Med* 1996;25:277-280.
76. Devine A, Dick IM, Dhaliwal SS, Naheed R, Beilby J, Prince RL. Prediction of incident osteoporotic fractures in elderly women using the free estradiol index. *Osteoporos Int* 2005;16:216-221.
77. Pouilles JM, Tremollieres F, Bonneau M, Ribot C. Influence of early age at menopause on vertebral bone mass. *J Bone Miner Res* 1994;9:311-315.
78. Ohta H, Sugimoto I, Masuda A, et al. Decreased bone mineral density associated with early menopause progresses for at least ten years: cross-sectional comparisons between early and normal menopausal women. *Bone* 1996;18:227-231.
79. Gerdhem P, Obrant KJ. Bone mineral density in old age: the influence of age at menarche and menopause. *J Bone Miner Metab* 2004;22:372-375.
80. Fujita K, Kasayama S, Hashimoto J, et al. Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women. *J Bone Miner Res* 2001;16:782-787.
81. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. *J Bone Miner Res* 2001;16:581-588.
82. Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. *Eur Respir J* 2002;19:1058-1063.
83. Kemp JP, Osur S, Shrewsbury SB, et al. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc* 2004;79:459-466.
84. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. *J Bone Miner Res* 2004;19:893-899.
85. Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. *Cochrane Database Syst Rev* 2003;4:CD001297.
86. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. *Fertil Steril* 2004;82:1580-1586.
87. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. *Epidemiology* 2002;13:581-587.
88. FDA Talk Paper. Black box warning added concerning long-term use of Depo-Provera contraceptive injection. Available at: <http://www.fda.gov/bbs/topics/answers/2004/ans01325.html>. Accessed January 16, 2006.
89. Siminoski K, Jiang G, Adachi JD, et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. *Osteoporos Int* 2005;16:403-410.
90. Wasnich RD. Vertebral fracture epidemiology. *Bone* 1996;18 (Suppl):179S-183S.
91. Wu CY, Li J, Jergas M, Genant HK. Comparison of semi-quantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. *Osteoporos Int* 1995;5:354-370.
92. Hedlund LR, Gallagher JC, Meeger C, Stoner S. Change in vertebral shape in spinal osteoporosis. *Calcif Tissue Int* 1989;44:168-172.
93. Majumdar SR, Kim N, Colman I, et al. Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients. *Arch Intern Med* 2005;165:905-909.
94. Schneider DL, von Muhlen D, Barrett-Connor E, Sartoris DJ. Kyphosis does not equal vertebral fractures: the Rancho Bernardo study. *J Rheumatol* 2004;31:747-752.
95. Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA. Instant vertebral assessment: a noninvasive dual x-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. *J Clin Densitom* 2001;4:373-380.
96. Ferrar L, Jiang G, Barrington NA, Eastell R. Identification of vertebral deformities in women: comparison of radiological assessment and quantitative morphometry using morphometric radiography and morphometric x-ray absorptiometry. *J Bone Miner Res* 2000;15:575-585.
97. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res* 1993;8:1137-1148.

98. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis: the Study of Osteoporotic Fractures Research Group. *J Bone Miner Res* 1996;11:984-996.
99. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis. *J Am Geriatr Soc* 1999;47:30-50.
100. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. *N Engl J Med* 1988;319:1701-1707.
101. Kanis JA, Borgstrom F, DeLaet C, et al. Assessment of fracture risk. *Osteoporos Int* 2005;16:581-589.
102. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. *JAMA* 2001;286:2815-2822.
103. Hodgson SF, Watts NB, Bilezikian JP, et al, for the American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. *Endocr Pract* 2001;7:293-312.
104. Knoke JD, Barrett-Connor E. Weight loss: a determinant of hip bone loss in older men and women. The Rancho Bernardo Study. *Am J Epidemiol* 2003;158:1132-1138.
105. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. *JAMA* 2000;283:1318-1321.
106. Delmas PD. Treatment of postmenopausal osteoporosis. *Lancet* 2002;359:2018-2026.
107. Marcus R, Holloway L, Wells B, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. *J Bone Miner Res* 1999;14:1583-1595.
108. Miller PD, Baran DT, Bilezikian JT, et al. Practical clinical applications of biochemical markers of bone turnover: consensus of an expert panel. *J Clin Densitom* 1999;2:323-342.
109. Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover? *Curr Med Res Opin* 2005;21:545-554.
110. Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. *Obstet Gynecol* 1997;89:321-325.
111. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J, for the Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. *Osteoporos Int* 2000;11(Suppl 6):S2-S17.
112. Ensrud KE, Ewing SK, Stone KL, Cauley JA, Bowman PJ, Cummings SR, for the Study of Osteoporotic Fractures Research Group. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. *J Am Geriatr Soc* 2003;51:1740-1747.
113. Hannan MT, Tucker KL, Dawson-Hughes B, Cupples LA, Felson DT, Kiel DP. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. *J Bone Miner Res* 2000;15:2504-2512.
114. Rapuri PB, Gallagher JC, Haynatzka V. Protein intake: effects on bone mineral density and the rate of bone loss in elderly women. *Am J Clin Nutr* 2003;77:1517-1525.
115. Tkatch L, Rapin CH, Rizzoli R, et al. Benefits of oral protein supplementation in elderly patients with fracture of the proximal femur. *J Am Coll Nutr* 1992;11:519-525.
116. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. *Am J Clin Nutr* 1998;67:18-24.
117. Jackson RD, LaCroix AZ, Gass M, et al, for the Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med* 2006;354:669-683.
118. National Institutes of Health. NIH Consensus Development Panel on Optimal Calcium Intake. Optimal calcium intake. *JAMA* 1994;272:1942-1948.
119. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Institute of Medicine. *Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*. Washington, DC: National Academy Press, 1997.
120. Alaimo K, McDowell MA, Briefel RR. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, phase 1, 1988-1991. *Adv Data* 1994; 258:1-28.
121. MacLean D. *The Report of the Nova Scotia Nutrition Survey*. Halifax, Nova Scotia: Nova Scotia Heart Health Program, Health and Welfare Canada, Nova Scotia Department of Health, 1993.
122. The North American Menopause Society. The role of calcium in peri- and postmenopausal women: consensus opinion of The North American Menopause Society. *Menopause* 2001;8: 84-95.
123. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. *Ann Intern Med* 1997;126:497-504.
124. National Osteoporosis Foundation. *Physician's Guide to Prevention and Treatment of Osteoporosis*. Washington, DC, 2003.
125. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int* 1997;7:439-443.
126. Gallagher JC, Kinyamu HK, Fowler SE, et al. Calcitropic hormones and bone markers in the elderly. *J Bone Miner Res* 1998;13:475-482.
127. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med* 1990;23:878-883.
128. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. *J Bone Miner Res* 2003;18:343-351.
129. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. *J Bone Miner Res* 2000;15:1113-1118.
130. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. *JAMA* 2004;291: 1999-2006.
131. Braam LA, Knapen MH, Geusens P, et al. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. *Calcif Tissue Int* 2003;73:21-26.
132. Spencer H, Fuller H, Norris C, Williams D. Effect of magnesium on the intestinal absorption of calcium in man. *J Am Coll Nutr* 1994;13:485-492.
133. Durlach J, Bac P, Durlach V, Rayssiguier Y, Bara M, Guet-Bara A. Magnesium status and ageing: an update. *Magnes Res* 1998;11:25-42.
134. Rude RK, Olerich M. Magnesium deficiency: possible role in osteoporosis associated with gluten-sensitive enteropathy. *Osteoporos Int* 1996;6:453-461.
135. The North American Menopause Society. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. *Menopause* 2000;7:215-229.
136. Krejnkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. *JAMA* 2004;292:65-74.
137. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect

- of soy protein isolate on bone metabolism. *Menopause* 2004; 11:290-298.
138. Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr* 2004;79:326-333.
 139. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. Ipriflavone Multicenter European Fracture Study. *JAMA* 2001;285:1482-1488.
 140. Verschueren SM, Roelants M, Delecluse C, Swinnen S, Vanderschueren D, Boonen S. Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. *J Bone Miner Res* 2004;19:352-359.
 141. Rubin C, Recker R, Cullen D, Ryaby J, McCabe J, McLeod K. Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. *J Bone Miner Res* 2004;19:343-351.
 142. Snow-Harter C, Bouxsein ML, Lewis BT, Carter DR, Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. *J Bone Miner Res* 1992;18:761-769.
 143. Kelley GA, Kelley KS, Tran ZV. Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data. *J Gerontol A Biol Sci Med Sci* 2002;57:599-604.
 144. Notelovitz M, Martin D, Tesar R, et al. Estrogen therapy and variable-resistance weight training increase bone mineral in surgically menopausal women. *J Bone Miner Res* 1991;6:583-590.
 145. Robertson MC, Campbell AJ, Gardner MM, Devlin N. Preventing injuries in older people by preventing falls: a meta-analysis of individual-level data. *J Am Geriatr Soc* 2002;50:905-911.
 146. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. *Lancet* 2002;359:1761-1767.
 147. O'Loughlin JL, Robitaille Y, Boivin JF, Suissa S. Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. *Am J Epidemiol* 1993;137:342-354.
 148. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. *Cochrane Database Syst Rev* 2003;4:CD000340.
 149. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized controlled trial. *J Am Geriatr Soc* 1999;47:850-853.
 150. Cameron ID, Cumming RG, Kurrle SE, et al. A randomized trial of hip protector use by frail older women living in their own homes. *Inj Prev* 2003;9:138-141.
 151. Parker MJ, Gillespie WJ, Gillespie LD. Hip protectors for preventing hip fractures in older people. *Cochrane Database Syst Rev* 2005;3:CD001255.
 152. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. *Maturitas* 2004;48:271-287.
 153. Tosteson ANA, Grove MR, Hammond CS. Early discontinuation of treatment for osteoporosis. *Am J Med* 2003;115:209-216.
 154. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. *Isr Med Assoc J* 2003;5:859-862.
 155. McClung M. Bisphosphonates. *Endocrinol Metab Clin North Am* 2003;32:253-271.
 156. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. *Aging (Milano)* 2000;12:1-12.
 157. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. *Calcif Tissue Int* 2002;71:103-111.
 158. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. *J Bone Miner Res* 2005;20:1315-1322.
 159. Boniva package insert. Roche Laboratories Inc; 2006.
 160. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized controlled trial. *Ann Intern Med* 1998;128:253-261.
 161. McClung MR, Wasnich RD, Hosking DJ, et al, for the Early Postmenopausal Intervention Cohort Study. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. *J Clin Endocrinol Metab* 2004;89:4879-4885.
 162. Liberman UA, Weiss SR, Broll JL. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. *N Engl J Med* 1995;333:1437-1443.
 163. Ensrud KE, Barrett-Connor EL, Schwartz A, for the Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. *J Bone Miner Res* 2004;19:1259-1269.
 164. Bone HG, Hosking D, Devogelaer JP, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. *N Engl J Med*;350:1189-1199.
 165. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. *Lancet* 1996;348:1531-1541.
 166. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. Fracture Intervention Trial Research Group. *J Clin Endocrinol Metab* 2000;85:4118-4124.
 167. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. *J Clin Endocrinol Metab* 1998;83:396-402.
 168. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. *Calcif Tissue Int* 2004;75:462-468.
 169. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. *Osteoporos Int* 2000;11:83-91.
 170. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. *N Engl J Med* 2001;344:333-340.
 171. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. *Bone* 2003;32:120-126.
 172. McClung MR, Wasnich RD, Recker R, et al, for the Oral Ibandronate Study Group. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. *J Bone Miner Res* 2004;19:11-18.
 173. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *J Bone Miner Res* 2004;19:1241-1249.
 174. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Research Advisory Group. *Osteoporos Int* 2001;12:140-151.
 175. Hodsman A, Adachi J, Olszynski W. Use of bisphosphonates in the treatment of osteoporosis: prevention and management of osteoporosis: consensus statements from the scientific advisory

- board of the Osteoporosis Society of Canada. *Can Med Assoc J* 1996;155(Suppl):S945-S948.
176. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. *J Clin Endocrinol Metab* 2005;90:1294-1304.
 177. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg* 2004;62:527-534.
 178. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S-B. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. *J Am Dent Assoc* 2005;136:1658-1668.
 179. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofac Surg* 2005;63:1567-1575.
 180. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. *Cancer* 2005;104:83-93.
 181. Wasnich RD, Bagger YZ, Hosking DJ, et al, for the Early Postmenopausal Intervention Cohort Study Group. Changes in bone density and turnover after alendronate or estrogen withdrawal. *Menopause* 2004;11:622-630.
 182. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med* 1997;337:1641-1647.
 183. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *JAMA* 1999;282:637-645.
 184. Delmas PD, Ensrud KE, Adachi JD, et al, for the Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. *J Clin Endocrinol Metab* 2002;87:3609-3617.
 185. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. *Arch Intern Med* 2002;162:1140-1143.
 186. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. *JAMA* 1999;281:2189-2197.
 187. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *Breast Cancer Res Treat* 2001;65:125-134.
 188. Martino S, Cauley JA, Barrett-Connor E, et al, for CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. *J Natl Cancer Inst* 2004;96:1751-1761.
 189. Grady D, Ettinger B, Moscarielli E, et al, for the Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. *Obstet Gynecol* 2004;104:837-844.
 190. Barrett-Connor E, Grady D, Sashegvi A, et al, for the MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. *JAMA* 2002;287:847-857.
 191. Neele SJ, Evertz R, DeValck-DeRoo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. *Bone* 2002;30:599-603.
 192. Siris ES, Harris ST, Eastell R, et al, for the Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. *J Bone Miner Res* 2005;20:1514-1524.
 193. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. *J Bone Miner Res* 2001;16:1846-1853.
 194. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. *Lancet* 1997;350:550-555.
 195. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001;344:1434-1441.
 196. Forteo package insert. Eli Lilly and Company; 2004.
 197. Black DM, Bilezikian JP, Ensrud KE, et al, for the PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med* 2005;353:555-565.
 198. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. *J Clin Endocrinol Metab* 2000;85:2129-2134.
 199. Ettinger B, SanMartin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. *J Bone Miner Res* 2004;19:745-751.
 200. Wells G, Tugwell P, Shea B, et al, for the Osteoporosis Methodology Group and the Osteoporosis Research Advisor Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocr Rev* 2002;23:529-539.
 201. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI. *JAMA* 1996;276:1389-1396.
 202. Cauley JA, Robbins J, Chen Z, et al, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA* 2003;290:1729-1738.
 203. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. *JAMA* 2002;287:2668-2676.
 204. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. *JAMA* 2003;290:1042-1048.
 205. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. *Obstet Gynecol* 2004;104:443-451.
 206. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized controlled trial. *Ann Intern Med* 1999;130:897-904.
 207. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss: Transdermal Estradiol Investigator Group. *Obstet Gynecol* 1999;94:330-336.
 208. Al-Azzawi F, Lees B, Thompson J, Stevenson JC. Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. *Menopause* 2005;12:331-339.
 209. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. *Ann Intern Med* 1992;117:1016-1037.

210. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. *JAMA* 2001;285:2891-2897.
211. Banks E, Beral V, Reeves G, Balkwill A, Barnes I, for the Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. *JAMA* 2004;291:2212-2220.
212. Anderson GL, Limacher M, Assaf AR, et al, for the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004;291:1701-1712.
213. Chlebowski RT, Hendrix SL, Langer RD, et al, for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. *JAMA* 2003;289:3243-3253.
214. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al, for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. *JAMA* 2003;289:2673-2684.
215. Manson JE, Hsia J, Hohnson KC, et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med* 2003;349:523-534.
216. Cushman M, Kuller LH, Prentice R, et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. *JAMA* 2004;292:1573-1580.
217. Shumaker SA, Legault C, Rapp SR, et al, for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA* 2003;289:2651-2662.
218. The North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. *Menopause* 2004;11:589-600.
219. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. *J Clin Endocrinol Metab* 2002;87:4914-4923.
220. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E, for the PEPi Safety Follow-up Study. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPi) Safety Follow-up Study. *Arch Intern Med* 2002;162:665-672.
221. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2002;137:875-883.
222. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. *Osteoporos Int* 2001;12:385-390.
223. Barrett-Connor E, Wehren LE, Siris ES, et al. Recency and duration of postmenopausal hormone therapy: effects of bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. *Menopause* 2003;10:412-419.
224. Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. *Obstet Gynecol* 2004;103:440-446.
225. Silverman SL. Calcitonin. *Endocrinol Metab Clin North Am* 2003;32:273-284.
226. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salmon calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. *BMJ* 1992;305:556-561.
227. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF study group. *Am J Med* 2000;109:267-276.
228. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. *Clin Ther* 1989;11:205-209.
229. Lyritys GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. *Clin J Pain* 1999;15:284-289.
230. Blau LA, Hoehns JD. Analgesic efficacy of calcitonin for vertebral pain. *Ann Pharmacother* 2003;37:564-570.
231. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effect in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. *J Clin Endocrinol Metab* 2000;85:720-726.
232. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risendronate and hormone replacement therapies on bone mineral density in postmenopausal women. *J Clin Endocrinol Metab* 2001;86:1890-1897.
233. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. *N Engl J Med* 2004;350:459-468.
234. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. *J Clin Endocrinol Metab* 2005;90:2816-2822.